Page last updated: 2024-12-06

zileuton

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Zileuton is a leukotriene inhibitor used for the treatment of asthma. It works by blocking the production of leukotrienes, which are chemicals that cause inflammation and narrowing of the airways. Zileuton was first synthesized in the 1980s by researchers at the Upjohn Company. It is a relatively selective inhibitor of 5-lipoxygenase, the enzyme responsible for the biosynthesis of leukotrienes. Zileuton is effective in reducing the symptoms of asthma, including wheezing, coughing, shortness of breath, and chest tightness. It is typically taken orally, usually twice a day. Zileuton is a relatively safe medication, but it can cause side effects such as headache, nausea, diarrhea, and liver problems. It is important to talk to your doctor about the risks and benefits of zileuton before taking it. Zileuton is an important medication for the treatment of asthma. It is often used in conjunction with other asthma medications, such as inhaled corticosteroids. Zileuton is studied to understand its mechanism of action, its efficacy in different populations, and its potential for use in other inflammatory diseases. '

Cross-References

ID SourceID
PubMed CID60490
CHEMBL ID93
CHEBI ID10112
SCHEMBL ID4209
SCHEMBL ID18251470
MeSH IDM0175142

Synonyms (144)

Synonym
AC-13198
zileutonum
CHEBI:10112 ,
(+-)-1-(1-benzo[b]thien-2-ylethyl)-1-hydroxyurea
n-[1-(benzo[b]thiophen-2-yl)ethyl]-n-hydroxyurea
1-[1-(1-benzothien-2-yl)ethyl]-1-hydroxyurea
HMS3393M20
BB 0261152
(+-)-1-(1-benzo(b)thien-2-ylethyl)-1-hydroxyurea
zyflo filmtab
abt-077
a 64077
leutrol
zyflo cr
cti-02
urea, n-(1-benzo(b)thien-2-ylethyl)-n-hydroxy-
ziluton
zyflo
(+/-)-1-(1-benzo[b]thien-2-ylethyl)-1-hydroxyurea
abbott 64077
urea, n-(1-benzo(b)thien-2-ylethyl)-n-hydroxy-, (+-)-
a-64077
zileutonum [inn-latin]
n-(1-benzo(b)thien-2-ylethyl)-n-hydroxyurea
MLS001424079
zileuton ,
smr000466377
MLS000759510
NCGC00159453-02
DB00744
zyflo (tn)
D00414
111406-87-2
zileuton (usp/inn)
PRESTWICK0_001090
urea, n-(1-benzo[b]thien-2-ylethyl)-n-hydroxy-
nsc730712
nsc-730712
zileuton, commercially available as 600 mg tablets
1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea
HMS2093H06
HMS2051M20
HMS2089J12
AKOS000280127
abbott-64077
nsc-759277
CHEMBL93 ,
bdbm50000541
n-(1-benzo[b]thien-2-ylethyl)-n-hydroxyurea
A802357
NCGC00159453-04
NCGC00159453-03
nsc 759277
nsc 730712
v1l22wve2s ,
zileuton [usan:usp:inn:ban]
unii-v1l22wve2s
cas-111406-87-2
dtxsid9023752 ,
tox21_301148
dtxcid003752
NCGC00255046-01
tox21_111680
nsc759277
pharmakon1600-01505906
1-(1-(benzo[b]thiophen-2-yl)ethyl)-1-hydroxyurea
HMS2235O04
CCG-100901
FT-0601582
STL373010
NCGC00159453-06
S1443
AKOS016340558
gtpl5297
HMS3369I17
zileuton [orange book]
zileuton [who-dd]
zileuton [usp monograph]
zileuton [usp-rs]
zileuton [usan]
zileuton [mart.]
zileuton [mi]
zileuton [inn]
zileuton [vandf]
urea, n-(1-benzo(b)thien-2-ylethyl)-n-hydroxy-, (+/-)-
(+/-)-1-(1-benzo(b)thien-2-ylethyl)-1-hydroxyurea
CCG-213571
AB00639921-06
HY-14164
CS-1563
MLS006011971
NC00151
BBL029070
SCHEMBL4209
NCGC00159453-05
tox21_111680_1
KS-1195
AB00639921-09
AB00639921-08
MWLSOWXNZPKENC-UHFFFAOYSA-N
n-(1-benzo[b]thien-2-ylethyl)-n-hydroxy-urea
AC-31490
AB00639921_11
AB00639921_10
mfcd00866097
J-002574
J-525169
n-(1-benzo(b)thien-2-yl-ethyl)-n-hydroxyurea
SR-01000759349-6
SR-01000759349-4
sr-01000759349
SR-01000759349-5
SCHEMBL18251470
zileuton, united states pharmacopeia (usp) reference standard
HMS3654J08
EN300-123022
zileuton, >=98% (hplc)
MRF-0000030
SBI-0206869.P001
HMS3714E07
()-1(1-benzo[b]thien-2-ylethyl)-1-hydroxyure
SW197531-3
( inverted exclamation marka)-1(1-benzo[b]thien-2-ylethyl)-1-hydroxyure
FT-0675903
BCP16199
Z1546610483
Q202998
AMY12540
BRD-A56359832-001-04-6
SB19083
HMS3872F13
STARBLD0016861
zileuton- bio-x
BZ164573
SY102131
1-[1-(2-benzothienyl)ethyl]-1-hydroxyurea
zileuton (usp monograph)
n-(1-(benzo(b)thiophen-2-yl)ethyl)-n-hydroxyurea
1-(1-(1-benzothien-2-yl)ethyl)-1-hydroxyurea
(+-)-n-hydroxy-n-(1-benzo(b)thien-2-ylethyl)-urea
zileuton (mart.)
zileuton (usan:usp:inn:ban)
zileuton (usp-rs)
zileutonum (inn-latin)

Research Excerpts

Overview

Zileuton (Zi) is a selective inhibitor of 5-lipoxygenase, an enzyme involved in the production of several inflammatory/pro-resolving lipid mediators. Zileuton was approved by the US FDA in 1996 for the treatment of asthma in adults and children.

ExcerptReferenceRelevance
"Zileuton is an FDA-approved drug for treating asthma and an ALOX5 inhibitor."( Zileuton inhibits arachidonate-5-lipoxygenase to exert antitumor effects in preclinical cervical cancer models.
Li, L; Wang, S; Xiao, Y; Xu, Z, 2021
)
2.79
"Zileuton is a 5-lipoxygenase inhibitor that reduces the levels of downstream pro-inflammatory cytokines."( Zileuton, a 5-Lipoxygenase Inhibitor, Attenuates Haemolysate-Induced BV-2 Cell Activation by Suppressing the MyD88/NF-κB Pathway.
Lin, CL; Su, HY; Tsai, HP; Tsai, YC, 2022
)
2.89
"Zileuton (Zi) is a selective inhibitor of 5-lipoxygenase, an enzyme involved in the production of several inflammatory/pro-resolving lipid mediators."( A 5-Lipoxygenase Inhibitor, Zileuton, Modulates Host Immune Responses and Improves Lung Function in a Model of Severe Acute Respiratory Syndrome (SARS) Induced by
Andrade, ACDSP; Barbosa, CLN; Costa, VV; Cruz, JS; da Silva, BLV; da Silva, GSF; de Souza-Costa, LP; Ferreira, R; Machado, FS; Oliveira, FBR; Oliveira, NFM; Pereira, RDD; Porto, SLT; Queiroz-Junior, CM; Rabelo, RAN; Santos, FRDS; Teixeira, MM; Umezu, HL, 2023
)
1.93
"Zileuton is an orally active, selective inhibitor of 5-lipoxygenase, which catalyzes the first step in the conversion of arachadonic acid into leukotrienes. "( Quantification of the 5-lipoxygenase inhibitor zileuton in human plasma using high performance liquid chromatography-tandem mass spectrometry.
Christians, U; Clavijo, CF; Galinkin, JL; Hoffman, K; Labovitz, E; Malik, P; Pian, P; Rzasa Lynn, R; Vinks, AA, 2013
)
2.09
"Zileuton is an inhibitor of the enzyme 5-lipoxygenase that catalyzes conversion of arachidonic acid to leukotrienes."( The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude.
Elstad, MR; Grissom, CK; Richer, LD, 2005
)
1.05
"Zileuton is a 5-lipoxygenase inhibitor approved by the US FDA in 1996 for the treatment of asthma in adults and children. "( Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma.
Cameron, CM; Dube, LM; Kasten, LE; Walton-Bowen, K; Watkins, PB, 2007
)
2.11
"Zileuton is a potent and specific inhibitor of 5-lipoxygenase, the first dedicated enzyme in the metabolism of arachidonic acid to the leukotrienes. "( Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase.
Albert, D; Braeckman, R; Carter, G; Dubé, L; Hansen, R; Rubin, P; Swanson, L, 1991
)
1.95

Effects

Zileuton has shown the ability to attenuate induced bronchospasm, produce some degree of bronchodilation, and provide antiinflammatory or steroid-sparing effects with both single doses (800 mg) and chronic treatment (400 and 600 mg qid)

ExcerptReferenceRelevance
"Zileuton has been demonstrated to act as an anti-inflammatory agent by virtue of its well-known ability to inhibit 5-lipoxygenase (5-LO). "( The cardioprotective effects of zileuton, a 5-lipoxygenase inhibitor, are mediated by COX-2 via activation of PKC delta.
Choi, HE; Kwak, HJ; Lim, HJ; Park, HY; Park, JH; Park, KM, 2010
)
2.09
"Zileuton has shown the ability to attenuate induced bronchospasm, produce some degree of bronchodilation, and provide antiinflammatory or steroid-sparing effects with both single doses (800 mg) and chronic treatment (400 and 600 mg qid). "( Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma.
Kamada, AK; Wenzel, SE,
)
3.02

Actions

ExcerptReferenceRelevance
"Zileuton can inhibit these effects by inhibiting ALOX5."( The ALOX5 inhibitor Zileuton regulates tumor-associated macrophage M2 polarization by JAK/STAT and inhibits pancreatic cancer invasion and metastasis.
Chang, J; Hu, WM; Li, W; Liu, SQ; Yang, Q; Yang, ZJ; Zhu, KF; Zhu, ZC, 2023
)
1.96

Treatment

Zileuton treatment significantly reduced the T/D-induced histopathological injury. Treatment with zileuton led to an 18% decrease in PGE-M. Zileuton pretreatment caused hepatomegaly and elevated liver peroxisomal KCN-insensitive palmitoyl CoA oxidase activity.

ExcerptReferenceRelevance
"Zileuton treatment did not induce any change in the steady state levels of amyloid-β precursor protein (APP), BACE1 or ADAM10."( Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model involvement of γ-secretase.
Chu, J; Praticò, D, 2011
)
1.09
"Only zileuton treatment significantly reduced the T/D-induced histopathological injury."( Effects of montelukast and zileuton on testicular torsion/detorsion injury in rats.
Acikgoz, S; Baba, F; Banoglu, ZN; Dengiz, GO; Isikdemir, F; Kelek, S; Kurcer, Z; Sipahi, EY, 2014
)
1.15
"Zileuton treatment inhibited 5-LO as measured ex vivo by ionophore-stimulated LTB4 levels in whole blood."( Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects.
Awni, WM; Cohn, J; Drazen, JM; Fischer, AR; Frantz, R; Israel, E; McFadden, CA, 1995
)
1.01
"Zileuton treatment blocked the increase in nasal symptoms after aspirin ingestion (maximum nasal symptom score of 1.6 +/- 0.6 with zileuton vs 5.5 +/- 0.9 with placebo [p < 0.0053])."( Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma.
Callery, JC; Cohn, J; Drazen, JM; Fischer, AR; Igarashi, Y; Kaliner, MA; Lilly, CM; Rosenberg, MA; Rubin, P; White, MV, 1994
)
1.01
"Zileuton treatment decreased baseline urinary LTE4 excretion from a mean of 469 +/- 141 pg/mg creatinine to 137 +/- 69 pg/mg creatinine (p < 0.02) and blunted the maximum increase in urinary LTE4 after ingestion of ASA (3,539 +/- 826 pg/mg creatinine versus 1,120 +/- 316 pg/mg creatinine [p < 0.01])."( The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.
Callery, JC; Cohn, J; Drazen, JM; Fischer, AR; Israel, E; Lilly, CM; Rosenberg, MA; Rubin, P; Shapiro, J, 1993
)
1.01
"Zileuton pretreatment caused hepatomegaly and elevated liver peroxisomal KCN-insensitive palmitoyl CoA oxidase activity in a dose-dependent manner."( Hepatic peroxisomal and drug metabolizing activity in CD-1 mice after oral treatment with a novel 5-lipoxygenase inhibitor.
Machinist, JM; Rodrigues, AD, 1996
)
1.02
"Treatment with zileuton led to an 18% decrease in PGE-M levels (P = 0.03); the combination of zileuton and celecoxib led to a 62% reduction in PGE-M levels (P < 0.001)."( Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.
Akpa, EG; Bosworth, BP; Boyle, JO; Brown, PH; Dannenberg, AJ; Duffield-Lillico, AJ; Kingsley, PJ; Knutson, A; Marnett, LJ; Milne, GL; Mohebati, A; Szabo, E; Zhou, XK, 2013
)
1.13
"Oral treatment of zileuton at 10 or 50 mg/kg significantly reduced cerebral water content and infarct volume. "( 5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9.
Chen, CM; Shi, SS; Tu, XK; Wang, CH; Yang, WZ, 2009
)
0.99
"Pretreatment with zileuton partially prevented the AA-induced LTB(4) and IL-6 release and increased neutral lipid content."( Zileuton prevents the activation of the leukotriene pathway and reduces sebaceous lipogenesis.
Alestas, T; Seltmann, H; Zouboulis, CC, 2010
)
2.13
"Treatment with Zileuton for 2 weeks significantly increased thromboxane B(2) levels from baseline levels of 267 +/- 54 microg/l to 389 +/- 62 microg/l after 2 weeks of treatment (P < 0.0002)."( Zileuton, a 5-lipoxygenase inhibitor, increases production of thromboxane A2 and platelet aggregation in patients with asthma.
Dev, A; Leong, AB; Wu, X, 2003
)
2.1
"Treatment with zileuton CR, 1,200 mg twice daily, resulted in a significant improvement in asthma control, and the safety and efficacy profile was similar to that observed with zileuton IR, 600 mg 4 times daily (Zyflo)."( Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study.
Berger, W; Casale, T; Corren, J; Dube, L; Kemp, J; LaVallee, N; Nelson, H; Stepanians, M; Walton-Bowen, K, 2007
)
1.07
"Treatment with zileuton altered the inflammatory response after antigen challenge. "( A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings.
Cohn, J; Dworski, RT; Fish, JE; Kane, GC; Kim, CJ; Murray, JJ; Peters, SP; Pollice, M; Sheller, JR, 1996
)
0.88

Toxicity

HSA irreversible alkylation represents a model for other proteins to be potentially toxic and thus may help explain zileuton hepatotoxicity. A lesser but not significantly different adverse event rate was reported in the Zileuton ER group than the Montelukast group.

ExcerptReferenceRelevance
" After reading this article, readers should have an understanding both of the general safety of anti-LTs and their specific adverse effects."( Safety of antileukotriene agents in asthma management.
Spector, SL, 2001
)
0.31
" Although most agents are safe and well tolerated when used properly, adverse effects may occur with use at higher dose levels."( Safety of antileukotriene agents in asthma management.
Spector, SL, 2001
)
0.31
"The results of clinical trials and real-world experience indicate that these agents are generally safe and well tolerated, with an incidence of adverse effects comparable with placebo."( Safety of antileukotriene agents in asthma management.
Spector, SL, 2001
)
0.31
" The in vitro and in vivo data presented here demonstrate the formation of 2-ABT from zileuton and its further bioactivation to a potentially toxic metabolite."( In vitro metabolism of 2-acetylbenzothiophene: relevance to zileuton hepatotoxicity.
Chordia, MD; Heasley, BH; Joshi, EM; Macdonald, TL, 2004
)
0.79
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" The use of a combination of inhaled corticosteroids, long-acting beta-agonists, systemic corticosteroids, and leukotriene modifier drugs stabilized underlying airways in preparation for a reasonably safe and accurate oral aspirin challenge."( Effect of leukotriene modifier drugs on the safety of oral aspirin challenges.
Ludington, E; Mehra, P; Simon, RA; Stevenson, DD; White, A, 2006
)
0.33
" The adverse event profile was similar in the two treatment groups."( The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study.
Busse, W; Calhoun, W; Dube, L; Harris, J; Panettieri, R; Peters-Golden, M; Russell, H; Walton-Bowen, K; Wenzel, S, 2007
)
0.64
" HSA irreversible alkylation represents a model for other proteins to be potentially toxic and thus may help explain zileuton hepatotoxicity."( Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity.
Chordia, MD; Li, F; Macdonald, TL; Woodling, KA, 2007
)
0.8
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" A lesser but not significantly different adverse event rate was reported in the Zileuton ER group than the Montelukast group with the commonest events being headache and gastrointestinal effects in both the groups."( A randomized, comparative, multicentric clinical trial to assess the efficacy and safety of zileuton extended-release tablets with montelukast sodium tablets in patients suffering from chronic persistent asthma.
Bhargava, S; Khippal, N; Kshatriya, RR; Kubavat, AH; Mittal, R; Patel, T; Rijhwani, P; Shah, N; Tak, S,
)
0.58

Pharmacokinetics

The relatively small pharmacokinetic effect of zileuton on terfenadine metabolism, with no change in the QTc interval, is unlikely to be of clinical significance. Coadministration did not significantly affect the area under the plasma concentration-time curve, the maximum (Cmax) or minimum (Cmin) plasma concentration and time to Cmax of SASP, SP or ASP.

ExcerptReferenceRelevance
" Patients had 6-h pharmacokinetic evaluation of zileuton on day 14."( Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis.
Awni, WM; Brandwein, SR; Dube, LM; Granneman, GR; Locke, CS, 1995
)
0.55
"The potential pharmacokinetic and pharmacodynamic interactions between zileuton, a 5-lipoxygenase inhibitor, and naproxen, a nonsteroidal anti-inflammatory drug that acts as a cyclo-oxygenase inhibitor, have been investigated in 24 healthy volunteers."( The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers.
Awni, WM; Braeckman, RA; Cavanaugh, JH; Dubé, LM; Granneman, GR; Linnen, PJ; Locke, CS, 1995
)
0.75
" Trough zileuton plasma concentrations (Cmin) immediately before the morning dose were higher than Cmin immediately before the afternoon dose, suggesting a diurnal variation in the pharmacokinetics of zileuton."( Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers.
Awni, WM; Braeckman, RA; Dubé, LM; Granneman, GR; Witt, G, 1995
)
0.99
" From the results of the present study, it is concluded that there is no pharmacokinetic basis for alteration of zileuton dosage schedules in elderly patients."( The pharmacokinetics of zileuton in healthy young and elderly volunteers.
Awni, WM; Braeckman, RA; Cavannaugh, JH; Granneman, GR; Locke, CS; Machinist, JM, 1995
)
0.81
"The present study was undertaken to assess the effect of food on the pharmacokinetic parameters of zileuton."( The effect of food on the pharmacokinetics of zileuton.
Awni, WM; Cavanaugh, JH; Dubé, LM; Granneman, GR; Witt, G, 1995
)
0.77
" Pharmacokinetic data were analysed utilising noncompartmental and Michaelis-Menten-based population pharmacokinetic analysis."( Lack of pharmacokinetic interaction between zileuton and phenytoin in humans.
Cavanaugh, JH; Granneman, GR; Mukherjee, D; Samara, E, 1995
)
0.55
" The pharmacokinetics of the N-dehydroxylated metabolite of zileuton were highly variable, with a more than dose-proportional increase in the mean dose-normalised Cmax and area under the concentration-time curve from zero to 24 hours."( The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers.
Awni, WM; Cavanaugh, JH; Dubé, LM; el-Shourbagy, T; Locke, CS; Wong, SL, 1995
)
0.79
"The effects of coadministration of zileuton on the pharmacokinetic profile of digoxin were investigated in a double-blind placebo-controlled crossover study in 12 healthy male volunteers."( Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans.
Awni, WM; Cavanaugh, JH; Dubé, LM; Granneman, GR; Hussein, Z, 1995
)
0.82
" Coadministration of zileuton did not significantly affect the area under the plasma concentration-time curve, the maximum (Cmax) or minimum (Cmin) plasma concentration and the time to Cmax of SASP, SP or ASP."( The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine.
Awni, WM; Braeckman, RA; Dubé, LM; Granneman, GR; Locke, CS, 1995
)
0.88
" The pharmacodynamic performance in the mouse of selected compounds was assessed using an ex vivo LTB4 assay and an adoptive peritoneal anaphylaxis assay at extended pretreat times."( Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.
Adams, JL; Breton, JJ; Brian, WR; Chabot-Fletcher, M; Garigipati, RS; Garver, E; Griswold, DE; Newton, JF; Schmidt, SJ; Sorenson, M; Tyrrell, KA; Tzimas, M; Webb, EF; Yodis, LA, 1996
)
0.29
" Coadministration of zileuton with terfenadine resulted in a significant increase in the mean AUC and Cmax of terfenadine by approximately 35% and the mean AUC and Cmax of carboxyterfenadine by approximately 15%."( The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine.
Awni, WM; Cao, G; Cavanaugh, JH; Dube, LM; Kasier, J; Leese, P; Locke, CS, 1997
)
0.86
"The relatively small pharmacokinetic effect of zileuton on terfenadine metabolism, with no change in the QTc interval, is unlikely to be of clinical significance."( The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine.
Awni, WM; Cao, G; Cavanaugh, JH; Dube, LM; Kasier, J; Leese, P; Locke, CS, 1997
)
0.8
"The diurnal variation in the pharmacokinetic parameters of zileuton were evaluated in 12 healthy male volunteers in a three-period study."( Evaluation of the diurnal variation in the pharmacokinetics of zileuton in healthy volunteers.
Awni, WM; Cavanaugh, JH; Dube, LM; Locke, C, 1997
)
0.78

Compound-Compound Interactions

ExcerptReferenceRelevance
" Treatment of rats with WEB, alone or in combination with Zileuton, did not attenuate ANIT-induced liver injury as assessed by increases in plasma alanine aminotransferase or gamma-glutamyl transferase activities."( Platelet activating factor receptor blockade alone or in combination with leukotriene synthesis inhibition does not ameliorate alpha-naphthylisothiocyanate-induced hepatotoxicity.
Bailie, MB; Fink, GD; Pearson, JM; Roth, RA, 1996
)
0.54

Bioavailability

Food has a relatively small effect on the rate of zileuton absorption compared with the fasting state, while the bioavailability of the drug appears to be unaffected. Zileuton was well absorbed orally with an elimination half-life of approximately 2.

ExcerptReferenceRelevance
" Compound 15, the open form of lactone 4b, is well absorbed in the rat and is transformed into the active species 4b."( Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids.
Brideau, C; Chan, CC; Dubé, D; Ducharme, Y; Falgueyret, JP; Gillard, JW; Guay, J; Hutchinson, JH; McFarlane, CS; Riendeau, D, 1994
)
0.29
" Such measurements, combined with bioavailability data from other species, may be useful for predicting biochemical activity in man."( Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors.
Black, C; Brideau, C; Chan, C; Ford-Hutchinson, A; Frenette, R; Tagari, P, 1993
)
0.29
" In addition, the compound exhibits excellent bioavailability in dogs and monkeys with a relatively long elimination half-life in both the species (6 and 3 h, respectively)."( The properties of A-69412: a small hydrophilic 5-lipoxygenase inhibitor.
Bell, RL; Bouska, J; Brooks, DW; Carter, GW; Lanni, C; Machinist, J; Malo, PE; Summers, JB; Young, PR, 1993
)
0.29
" Overall, the results suggest that food has a relatively small effect on the rate of zileuton absorption compared with the fasting state, while the bioavailability of the drug appears to be unaffected."( The effect of food on the pharmacokinetics of zileuton.
Awni, WM; Cavanaugh, JH; Dubé, LM; Granneman, GR; Witt, G, 1995
)
0.77
"Representative nonsteroidal anti-inflammatory drug (NSAID) cyclooxygenase inhibitors such as ibuprofen, naproxen, and indomethacin were used as orally bioavailable scaffolds to design selective 5-lipoxygenase (5-LO) inhibitors."( Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors.
Bell, RL; Bouska, J; Brooks, CD; Carter, GW; Dellaria, JF; Hulkower, KI; Kolasa, T; Rodriques, KE; Summers, JB, 1997
)
0.3
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Both S-29606 and S-30621 were dosed via nose-only inhalation 5 days a week, for 16 weeks. Zileuton was administered orally. No overall differences were observed between the zileuton dosage groups.

ExcerptRelevanceReference
" In the rat 4f inhibited LTB4 synthesis in blood ex vivo and in zymosan-inflamed air pouch exudate with an ED50 3 h after oral dosing of 10 mg/kg in each system."( Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors.
Bird, TG; Bruneau, P; Crawley, GC; Dowell, RI; Edwards, PN; Foster, SJ; Giroaeau, JM; McMillan, RM; Walker, ER; Waterson, D, 1992
)
0.28
" The peak concentrations and the areas under the curves during the dosing interval were dose proportional."( Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis.
Awni, WM; Brandwein, SR; Dube, LM; Granneman, GR; Locke, CS, 1995
)
0.29
" From the results of the present study, it is concluded that there is no pharmacokinetic basis for alteration of zileuton dosage schedules in elderly patients."( The pharmacokinetics of zileuton in healthy young and elderly volunteers.
Awni, WM; Braeckman, RA; Cavannaugh, JH; Granneman, GR; Locke, CS; Machinist, JM, 1995
)
0.81
" Upon initiation of zileuton, the typical asthma patient may require dosage reductions of one-half, and monitoring of plasma theophylline concentrations is recommended."( Effect of zileuton on theophylline pharmacokinetics.
Awni, WM; Braeckman, RA; Cavanaugh, JH; Dubé, LM; Granneman, GR; Locke, CS, 1995
)
1.02
" Monkeys (n = 6 each group) were dosed with vehicle, 3 or 10 mg/kg ZD2138, or 30 mg/kg Zileuton (p."( The effect of 5-lipoxygenase inhibition on Ascaris antigen (Ag)-induced responses in atopic monkeys.
Andresen, CJ; Eggler, JF; Smith, WB; Turner, CR; Watson, JW, 1996
)
0.52
" In rats and dogs, 3g presents excellent pharmacokinetics (estimated half-lives of 5 and 16 h, respectively) and bioavailabilities (26% and 73% when dosed as its hydrochloride salt at doses of 20 and 10 mg/kg, respectively, in methocel suspension)."( Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010.
Brideau, C; Chan, CC; Delorme, D; Desmarais, S; Dubé, D; Ducharme, Y; Ethier, D; Falgueyret, JP; Girard, Y; Grimm, E; Guay, J; Hamel, P; Jones, TR; Kwong, E; McAuliffe, M; McFarlane, CS; Piechuta, H; Riendeau, D; Roumi, M; Tagari, P; Young, RN, 1997
)
0.3
" Further studies performed in human liver microsomes demonstrated a similar trend that was corroborated by the 8-fold increase in duration after oral dosing in humans observed with ABT-761."( Improving the in vivo duration of 5-lipoxygenase inhibitors: application of an in vitro glucuronosyltransferase assay.
Bell, RL; Bouska, JJ; Brooks, CD; Carter, GW; Goodfellow, CL; Stewart, AO, 1997
)
0.3
" Initially, the theophylline dosage was titrated to achieve trough concentrations of 8 to 15 micrograms/mL."( A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group.
Dubé, LM; Lancaster, JF; Petty, T; Schwartz, HJ; Swanson, LJ, 1998
)
0.57
" No overall differences were observed between the zileuton dosage groups."( A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group.
Dubé, LM; Lancaster, JF; Petty, T; Schwartz, HJ; Swanson, LJ, 1998
)
0.82
" Therefore, in this study, we determined if multiple dosing with zileuton, which theoretically could improve tissue levels, would provide protection against the antigen-induced EAR as well as the LAR."( The effects of multiple dosing with zileuton on antigen-induced responses in sheep.
Abraham, WM; Allegra, L; Scuri, M, 1998
)
0.81
" Patients who demonstrate improved asthma control with zileuton 600 mg QID may be able to reduce their daily dosage and/or frequency while still maintaining the same level of symptom control."( Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group.
Dubé, LM; DuBuske, LM; Grossman, J; Lancaster, JF; Swanson, LJ, 1997
)
0.87
" LC/MS analyses of urine samples collected from rats dosed with zileuton indicate that C1 is a metabolite of zileuton formed in vivo."( In vitro metabolism of 2-acetylbenzothiophene: relevance to zileuton hepatotoxicity.
Chordia, MD; Heasley, BH; Joshi, EM; Macdonald, TL, 2004
)
0.8
" Both S-29606 and S-30621 were dosed via nose-only inhalation 5 days a week, for 16 weeks, whereas Zileuton was administered orally."( Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation.
Angersbach, BS; Karlage, K; Kuehl, PJ; Merrill, BA; Myrdal, PB; Wightman, PD, 2007
)
0.56
" dosing and an intravenous preparation for acute asthma exacerbations may enhance clinical utility and expand therapeutic indications."( Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease.
Berger, W; Cairns, CB; De Chandt, MT, 2007
)
1.78
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
" In the rat air pouch model, oral dosing of CJ-13,610 and zileuton resulted in selective inhibition 5-LOX activity from pouch exudate and ex vivo rat whole blood with similar potency to in vitro assay."( A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
Anderson, GD; Dufield, DR; Hardy, MM; Masferrer, JL; Pufahl, RA; Zweifel, BS, 2008
)
0.59
" Finally, these compounds have shown efficacy when dosed orally in multiple acute and chronic prostaglandin and leukotriene dependent in vivo models."( Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib.
Abraham, WM; Albert, L; Behnke, ML; Chen, L; Clark, JD; Donahue, F; Foley, MA; Goodwin, DG; Hegen, M; Hu, B; Hu, Y; Ipek, M; Keith, J; Kirincich, SJ; Ku, MS; Lee, KL; McKew, JC; Michalak, R; Murphy, EA; Nickerson-Nutter, CL; Ramarao, MK; Shen, MW; Sum, FW; Tam, S; Thakker, P; Thomason, J; Williams, C; Wooder, L; Wu, K; Xu, X, 2008
)
0.35
" Previous research from the authors' laboratory demonstrated the formation of the reactive metabolite, 2-ABT-S-oxide (M1) from zileuton, and has identified a mercapturate of 2-ABT, C1, in the urine of rats dosed with zileuton."( 2-ABT-S-oxide detoxification by glutathione S-transferases A1-1, M1-1 and P1-1: implications for toxicity associated with zileuton.
Heasley, BH; Joshi, EM; Macdonald, TL, 2009
)
0.77
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" Naringenin, naringenin chalcone, and quercetin all showed strong antiallergic activity after intravenous dosing (0."( In Vivo Anti-inflammatory and Antiallergic Activity of Pure Naringenin, Naringenin Chalcone, and Quercetin in Mice.
Boix Montañés, A; Escribano-Ferrer, E; Garcia-Sala, X; Lamuela-Raventos, RM; Queralt Regué, J, 2019
)
0.51
" Further studies are warranted to optimize drug delivery and dosing in humans."( Zileuton ameliorates aminoglycoside and polymyxin-associated acute kidney injury in an animal model.
Eales, BM; Hudson, CS; Kajiji, S; Liu, X; Smith, JE; Tam, VH; Truong, LD, 2023
)
2.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitorA lipoxygenase inhibitor that interferes with the action of arachidonate 5-lipoxygenase (EC 1.13.11.34).
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
anti-asthmatic drugA drug used to treat asthma.
leukotriene antagonistA drug designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level.
ferroptosis inhibitorAny substance that inhibits the process of ferroptosis (a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides) in organisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
ureas
1-benzothiophenes
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (47)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency1.73770.002541.796015,848.9004AID1347399
GALC proteinHomo sapiens (human)Potency0.707928.183828.183828.1838AID1159614
GLI family zinc finger 3Homo sapiens (human)Potency11.88320.000714.592883.7951AID1259369
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency22.42100.001022.650876.6163AID1224838; AID1224839; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency13.80290.01237.983543.2770AID1645841
pregnane X nuclear receptorHomo sapiens (human)Potency34.37620.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency5.49410.000229.305416,493.5996AID743075
GVesicular stomatitis virusPotency24.54540.01238.964839.8107AID1645842
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency11.42470.001019.414170.9645AID743094; AID743140
aryl hydrocarbon receptorHomo sapiens (human)Potency32.82740.000723.06741,258.9301AID743085; AID743122
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency12.58930.036619.637650.1187AID2100
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency12.58930.01789.637444.6684AID588834
lamin isoform A-delta10Homo sapiens (human)Potency0.22390.891312.067628.1838AID1487
Interferon betaHomo sapiens (human)Potency19.70870.00339.158239.8107AID1347407; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency24.54540.01238.964839.8107AID1645842
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency6.30960.009610.525035.4813AID1479145
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency24.54540.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency24.54540.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin E synthaseHomo sapiens (human)IC50 (µMol)0.60000.00102.030810.0000AID1406495
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)564.40000.40002.75008.6000AID1209456
Bile salt export pumpHomo sapiens (human)IC50 (µMol)628.06670.11007.190310.0000AID1209455; AID1449628; AID1473738
Cytochrome P450 1A2Homo sapiens (human)Ki117.00000.00561.15349.0000AID589217
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)150.00000.00032.177410.0000AID1801112
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)IC50 (µMol)4.40440.00011.68479.3200AID104155; AID104156; AID1057566; AID1057567; AID1065366; AID1065367; AID1065368; AID1065370; AID1067164; AID1073063; AID1126817; AID1139553; AID1139554; AID1139555; AID1143900; AID1143907; AID1152197; AID1201309; AID1201310; AID1201312; AID1244230; AID1244232; AID1287592; AID1333392; AID1406145; AID1420842; AID1424048; AID1461764; AID1461765; AID1478501; AID1484241; AID1484242; AID1512367; AID1543288; AID1608445; AID1614267; AID1614268; AID1615195; AID1615865; AID1617774; AID1676587; AID1703351; AID1703353; AID1704054; AID1717041; AID1736439; AID1799727; AID1801075; AID1819014; AID241982; AID372021; AID372022; AID412945; AID427632; AID475089; AID620273; AID650765; AID661902; AID661903; AID6694; AID6709; AID6725; AID6728; AID6732; AID688620; AID6948; AID6949; AID6955; AID698652; AID698653; AID713974; AID730632; AID775842; AID89122
Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)100.00000.00051.28547.6500AID99747
Polyunsaturated fatty acid 5-lipoxygenaseRattus norvegicus (Norway rat)IC50 (µMol)0.96560.00462.018210.0000AID1268103; AID1411791; AID1488612; AID1549679; AID290450; AID3637; AID6787; AID6821; AID6861; AID7057; AID7065; AID7069; AID7094; AID7096; AID7101
Polyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)IC50 (µMol)0.40000.04002.099810.0000AID1443721
Polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)IC50 (µMol)55.00000.10002.452310.0000AID3103
Arachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)IC50 (µMol)0.58000.00160.07630.5800AID1287591
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)10.00000.00021.557410.0000AID161677
Bifunctional epoxide hydrolase 2Homo sapiens (human)IC50 (µMol)0.59100.00000.54509.1000AID736008
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)80.00000.00010.995010.0000AID162669; AID1801112
Polyunsaturated fatty acid 5-lipoxygenaseMus musculus (house mouse)IC50 (µMol)0.19000.00800.15750.4000AID1253309
Thromboxane-A synthaseRattus norvegicus (Norway rat)IC50 (µMol)20.00000.00400.39231.5000AID228240
Leukotriene B4 receptor 1Homo sapiens (human)IC50 (µMol)0.42000.00080.30913.2500AID102653
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Acyl-CoA:cholesterol acyltransferase Oryctolagus cuniculus (rabbit)IC50 (µMol)55.00000.00600.98467.6000AID3103
Cysteinyl leukotriene receptor 2Homo sapiens (human)IC50 (µMol)0.42000.00102.405210.0000AID102653
Cysteinyl leukotriene receptor 1Homo sapiens (human)IC50 (µMol)0.42000.00030.948710.0000AID102653
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)EC50 (µMol)0.47000.07002.86006.8000AID101298
Leukotriene B4 receptor 1Homo sapiens (human)EC50 (µMol)0.47000.07002.44676.8000AID101298
Leukotriene B4 receptor 2Homo sapiens (human)EC50 (µMol)0.47000.07001.93756.8000AID101298
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin G/H synthase 1 Bos taurus (cattle)ID50750.00000.43003.66506.9000AID160715
Prostaglandin G/H synthase 2 Bos taurus (cattle)ID50750.00000.43003.66506.9000AID160715
Polyunsaturated fatty acid 5-lipoxygenaseRattus norvegicus (Norway rat)Change0.35000.30003.566710.0000AID6772; AID6773
Polyunsaturated fatty acid 5-lipoxygenaseRattus norvegicus (Norway rat)ID500.14000.14000.31000.4800AID3622
Prostaglandin G/H synthase 2 Rattus norvegicus (Norway rat)Change16.00000.10002.60008.0000AID160868
Prostaglandin G/H synthase 1 Rattus norvegicus (Norway rat)Change16.00000.10002.60008.0000AID160868
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (263)

Processvia Protein(s)Taxonomy
prostaglandin biosynthetic processProstaglandin E synthaseHomo sapiens (human)
prostaglandin metabolic processProstaglandin E synthaseHomo sapiens (human)
signal transductionProstaglandin E synthaseHomo sapiens (human)
cell population proliferationProstaglandin E synthaseHomo sapiens (human)
negative regulation of cell population proliferationProstaglandin E synthaseHomo sapiens (human)
sensory perception of painProstaglandin E synthaseHomo sapiens (human)
regulation of fever generationProstaglandin E synthaseHomo sapiens (human)
positive regulation of prostaglandin secretionProstaglandin E synthaseHomo sapiens (human)
regulation of inflammatory responseProstaglandin E synthaseHomo sapiens (human)
cellular oxidant detoxificationProstaglandin E synthaseHomo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 1 Bos taurus (cattle)
meiotic spindle organizationProstaglandin G/H synthase 2 Bos taurus (cattle)
prostaglandin biosynthetic processProstaglandin G/H synthase 2 Bos taurus (cattle)
ovarian cumulus expansionProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of protein phosphorylationProstaglandin G/H synthase 2 Bos taurus (cattle)
response to oxidative stressProstaglandin G/H synthase 2 Bos taurus (cattle)
cyclooxygenase pathwayProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of embryonic developmentProstaglandin G/H synthase 2 Bos taurus (cattle)
cellular response to interleukin-1Prostaglandin G/H synthase 2 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 2 Bos taurus (cattle)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of oocyte maturationProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of meiotic cell cycle process involved in oocyte maturationProstaglandin G/H synthase 2 Bos taurus (cattle)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
proteolysisLeukotriene A-4 hydrolaseHomo sapiens (human)
lipid metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to zinc ionLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene biosynthetic processLeukotriene A-4 hydrolaseHomo sapiens (human)
protein metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
peptide catabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to peptide hormoneLeukotriene A-4 hydrolaseHomo sapiens (human)
type I pneumocyte differentiationLeukotriene A-4 hydrolaseHomo sapiens (human)
ossificationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
negative regulation of adaptive immune responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
phosphatidylethanolamine biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
inflammatory responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of cell-substrate adhesionPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
fatty acid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
bone mineralizationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of actin filament polymerizationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
response to endoplasmic reticulum stressPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cellular response to interleukin-13Polyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
wound healingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
apoptotic cell clearancePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cellular response to calcium ionPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of engulfment of apoptotic cellPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
leukotriene A4 metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
negative regulation of muscle cell apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
fatty acid oxidationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
unsaturated fatty acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
superoxide anion generationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
establishment of skin barrierPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
negative regulation of platelet aggregationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
leukotriene A4 metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxin B4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
leukotriene production involved in inflammatory responseArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
positive regulation of acute inflammatory responseArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
leukotriene biosynthetic processArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
lipoxygenase pathwayArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
protein homotrimerizationArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
cellular response to calcium ionArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
cellular oxidant detoxificationArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
response to toxic substanceBifunctional epoxide hydrolase 2Homo sapiens (human)
positive regulation of gene expressionBifunctional epoxide hydrolase 2Homo sapiens (human)
dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
cholesterol homeostasisBifunctional epoxide hydrolase 2Homo sapiens (human)
stilbene catabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
phospholipid dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
regulation of cholesterol metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
muscle contractionLeukotriene B4 receptor 1Homo sapiens (human)
inflammatory responseLeukotriene B4 receptor 1Homo sapiens (human)
immune responseLeukotriene B4 receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
neuropeptide signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
chemotaxisLeukotriene B4 receptor 2Homo sapiens (human)
negative regulation of adenylate cyclase activityLeukotriene B4 receptor 2Homo sapiens (human)
keratinocyte migrationLeukotriene B4 receptor 2Homo sapiens (human)
leukotriene signaling pathwayLeukotriene B4 receptor 2Homo sapiens (human)
neuropeptide signaling pathwayLeukotriene B4 receptor 2Homo sapiens (human)
immune responseCysteinyl leukotriene receptor 2Homo sapiens (human)
leukotriene signaling pathwayCysteinyl leukotriene receptor 2Homo sapiens (human)
neuropeptide signaling pathwayCysteinyl leukotriene receptor 2Homo sapiens (human)
inflammatory response to antigenic stimulusCysteinyl leukotriene receptor 1Homo sapiens (human)
calcium ion transportCysteinyl leukotriene receptor 1Homo sapiens (human)
chemotaxisCysteinyl leukotriene receptor 1Homo sapiens (human)
defense responseCysteinyl leukotriene receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationCysteinyl leukotriene receptor 1Homo sapiens (human)
respiratory gaseous exchange by respiratory systemCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of angiogenesisCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of vasoconstrictionCysteinyl leukotriene receptor 1Homo sapiens (human)
establishment of localization in cellCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of glial cell proliferationCysteinyl leukotriene receptor 1Homo sapiens (human)
leukotriene signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
cellular response to hypoxiaCysteinyl leukotriene receptor 1Homo sapiens (human)
neuropeptide signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (95)

Processvia Protein(s)Taxonomy
glutathione transferase activityProstaglandin E synthaseHomo sapiens (human)
glutathione peroxidase activityProstaglandin E synthaseHomo sapiens (human)
prostaglandin-D synthase activityProstaglandin E synthaseHomo sapiens (human)
protein bindingProstaglandin E synthaseHomo sapiens (human)
glutathione bindingProstaglandin E synthaseHomo sapiens (human)
prostaglandin-E synthase activityProstaglandin E synthaseHomo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
peroxidase activityProstaglandin G/H synthase 2 Bos taurus (cattle)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 2 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 2 Bos taurus (cattle)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
RNA bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
epoxide hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene-A4 hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
protein bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
peptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
zinc ion bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
tripeptide aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
metalloaminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
hepoxilin-epoxide hydrolase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
arachidonate 5-lipoxygenase activityArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
protein bindingArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
enzyme activator activityArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
enzyme bindingArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
identical protein bindingArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
protein-containing complex bindingArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
arachidonic acid bindingArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
glutathione transferase activityArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
glutathione peroxidase activityArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
leukotriene-C4 synthase activityArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
magnesium ion bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide hydrolase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
toxic substance bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lipid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
protein homodimerization activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lysophosphatidic acid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
nucleotide bindingLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene B4 receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene receptor activityLeukotriene B4 receptor 2Homo sapiens (human)
leukotriene B4 receptor activityLeukotriene B4 receptor 2Homo sapiens (human)
G protein-coupled peptide receptor activityLeukotriene B4 receptor 2Homo sapiens (human)
leukotriene receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
protein bindingCysteinyl leukotriene receptor 2Homo sapiens (human)
cysteinyl leukotriene receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
G protein-coupled peptide receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
leukotriene receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
cysteinyl leukotriene receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (56)

Processvia Protein(s)Taxonomy
nuclear envelope lumenProstaglandin E synthaseHomo sapiens (human)
endoplasmic reticulum membraneProstaglandin E synthaseHomo sapiens (human)
membraneProstaglandin E synthaseHomo sapiens (human)
perinuclear region of cytoplasmProstaglandin E synthaseHomo sapiens (human)
membraneProstaglandin E synthaseHomo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1 Bos taurus (cattle)
nuclear inner membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
nuclear outer membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
endoplasmic reticulum membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular regionLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleoplasmLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
extracellular exosomeLeukotriene A-4 hydrolaseHomo sapiens (human)
tertiary granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
ficolin-1-rich granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleusLeukotriene A-4 hydrolaseHomo sapiens (human)
lipid dropletPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytoplasmic side of plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytoplasmPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
sarcolemmaPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
sarcolemmaPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
nuclear envelopeArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
endoplasmic reticulumArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
endoplasmic reticulum membraneArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
membraneArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
nuclear membraneArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
nuclear envelopeArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
endoplasmic reticulumArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomal matrixBifunctional epoxide hydrolase 2Homo sapiens (human)
cytosolBifunctional epoxide hydrolase 2Homo sapiens (human)
extracellular exosomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneLeukotriene B4 receptor 1Homo sapiens (human)
plasma membraneLeukotriene B4 receptor 1Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
nucleoplasmLeukotriene B4 receptor 2Homo sapiens (human)
plasma membraneLeukotriene B4 receptor 2Homo sapiens (human)
membraneLeukotriene B4 receptor 2Homo sapiens (human)
plasma membraneLeukotriene B4 receptor 2Homo sapiens (human)
cellular_componentCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (478)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID19921Duration of action was defined as the period of time from maximum inhibition of A-23187-stimulated LTB4 formation to the time where 50% of maximum inhibition is reached1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
AID290450Inhibition of 5-LOX in rat peritoneal leukocytes2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Indole derivatives as potent inhibitors of 5-lipoxygenase: design, synthesis, biological evaluation, and molecular modeling.
AID133505Glucuronidation rates in mouse liver microsomes1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.
AID1065366Inhibition of 5-LO (unknown origin)2013European journal of medicinal chemistry, Sep, Volume: 67Discovery and biological evaluation of novel 1,4-benzoquinone and related resorcinol derivatives that inhibit 5-lipoxygenase.
AID1676602Binding affinity to ferric ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID754977Inhibition of human leukocyte 5-LOX pseudoperoxidase activity assessed as reduction of active ferric ion to inactive ferrous state measured decomposition of 13-(S)-HPODE at 40 uM after 30 mins by iron-xylenol orange staining assay2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases.
AID92734Effect on production of LTB4 in human whole blood1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Thiopyrano[2,3,4-cd]indoles as 5-lipoxygenase inhibitors: synthesis, biological profile, and resolution of 2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5 -dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acid.
AID1810790Inhibition of soybean LOX using arachidonic acid as substrate incubated for 5 mins2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Design, Synthesis, and Activity Evaluation of Stereoconfigured Tartarate Derivatives as Potential Anti-inflammatory Agents
AID1858308Anti-inflammatory activity against OVA-sensitized asthmatic BALB/c mouse model assessed as inhibition of airway hyperreactivity to carbachol at 35 mg/kg, ip administered 30 mins prior to OVA challenge on days 0 and 7 and measured on day 21
AID7101Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.
AID1819013Inhibition of 5-LO in A23187-stimulated human HEK293 cells assessed as reduction in 5-LO product level at 1 uM preincubated for 5 mins followed by A23187, arachidonic acid addition and measured after 15 mins by RP-HPLC analysis relative to control2022Journal of natural products, 01-28, Volume: 85, Issue:1
Structure-Activity Relationship Studies of New Sinapic Acid Phenethyl Ester Analogues Targeting the Biosynthesis of 5-Lipoxygenase Products: The Role of Phenolic Moiety, Ester Function, and Bioisosterism.
AID80594In vivo activity in the leukotriene-dependent phase of allergen-induced bronchoconstriction in Guinea pigs total pulmonary resistance(RL) measured as percent inhibition at 50 micro mol/kg per os after 5 hours1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application i
AID92736In vitro activities of TXB2 in human platelets; Not tested1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1484239Anti inflammatory activity in CD-1 mouse assessed as reduction in zymosan-induced LTC4 by measuring LTC4 level in peritoneal exudates at 10 mg/kg, ip preincubated for 30 mins followed by zymosan addition measured after 30 mins by enzyme immunoassay (Rvb =2017Journal of natural products, 03-24, Volume: 80, Issue:3
Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones.
AID1615865Inhibition of recombinant human 5-lipoxygenase expressed in Escherichia coli BL21 (DE3) cells using arachidonic acid as substrate preincubated for 10 mins followed by susbtrate addition and measured after 10 mins by reverse phase HPLC method2019Journal of natural products, 09-27, Volume: 82, Issue:9
Myxochelin- and Pseudochelin-Derived Lipoxygenase Inhibitors from a Genetically Engineered
AID1287593Acute cytotoxicity against human neutrophils assessed as cell viability measured for 30 mins by trypan blue exclusion method2016European journal of medicinal chemistry, May-04, Volume: 1134,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP).
AID754975Inhibition of N-terminal His6-tagged human reticulocyte 15-LOX1 pseudoperoxidase activity assessed as reduction of active ferric ion to inactive ferrous state measured decomposition of 13-(S)-HPODE at 40 uM after 30 mins by iron-xylenol orange staining as2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1703353Inhibition of 5-LO in human PMNL cells assessed as reduction in LTB4, 5-H(P)ETE, 12-HETE and 15-HETE products formation using arachidonic acid as substrate preincubated for 10 mins followed by addition of substrate and measured after 10 mins by RP-HPLC me2020European journal of medicinal chemistry, Sep-15, Volume: 202Structure-based design, semi-synthesis and anti-inflammatory activity of tocotrienolic amides as 5-lipoxygenase inhibitors.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID240850Inhibition of 5-lipoxygenase activity in human whole blood assay2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1201310Inhibition of 5-LOX in A23187-stimulated human blood PMNL assessed as reduction in lipoxygenase products formation pre-incubated for 15 mins followed by stimulation with A23187 for 10 mins by RP-HPLC based cell based assay2015European journal of medicinal chemistry, Apr-13, Volume: 94Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.
AID404480Inhibition of PGF2alpha production in mouse MC9 cells2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib.
AID3103Inhibitory concentration against human platelet 12-lipoxygenase1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors.
AID161834Inhibition activity against recombinant human Prostaglandin G/H synthase 11997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors.
AID488201Inhibition of COX1 in human whole blood assessed as inhibition of 12-hydroxyheptadecatrienoic acid production by HPLC method2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Synthesis and biological activity of N-aroyl-tetrahydro-gamma-carbolines.
AID228240Inhibitory concentration against human platelet thromboxane synthetase1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors.
AID139271Maximum inhibition of LTB4 at dose 2 mg/kg in mouse1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.
AID1615195Inhibition of 5-LO in human PMNL cells assessed as reduction in leukotriene formation preincubated for 5 mins followed by thapsigargin stimulation measured after 15 mins by RP-HPLC analysis2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery of a novel 2,5-dihydroxycinnamic acid-based 5-lipoxygenase inhibitor that induces apoptosis and may impair autophagic flux in RCC4 renal cancer cells.
AID669531Inhibition of 5-lipoxygenase/FLAP in calcium ionophore-stimulated human whole blood assessed as residual LTB4 level at 5 uM preincubated for 15 mins prior to calcium ionophore-stimulation measured after 15 mins by LC-MS/MS analysis2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
Structure-activity relationship of nonacidic quinazolinone inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1).
AID1420842Inhibition of recombinant human 5-LOX expressed in Escherichia coli BL21 using arachidonic acid as substrate by UV-vis spectrophotometric method2018European journal of medicinal chemistry, Oct-05, Volume: 158Design, synthesis and identification of novel substituted 2-amino thiazole analogues as potential anti-inflammatory agents targeting 5-lipoxygenase.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1617775Inhibition of human recombinant 5-LOX expressed in insect cells assessed residual activity using arachidonic acid at 42 uM as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by ferric ion oxidation-xylenol o2019Journal of natural products, 12-27, Volume: 82, Issue:12
Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID131049Inhibition of Leukotriene formation in mouse adoptive peritoneal anaphylaxis assay ex vivo1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.
AID775828Inhibition of TPCK-treated trypsin (unknown origin) at 10 uM preincubated for 10 mins prior to substrate addition measured for 30 mins by spectrophotometric analysis2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Investigating the selectivity of metalloenzyme inhibitors.
AID404463Effect on prostaglandin production in mouse MC9 cells2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib.
AID372021Inhibition of 5-lipoxygenase in A-23817-challenged human neutrophils assessed as 5LO product formation by intact cell based assay in presence of exogenous arachidonic acid2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID131186Compound was tested to inhibit Leukotriene formation in A-23187-stimulated mouse whole blood using LTB4 specific RIA ex vivo1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.
AID1614267Inhibition of recombinant human 5-LOX expressed in Escherichia coli using arachidonic acid as substrate by UV-vis spectrophotometric method2019Bioorganic & medicinal chemistry, 02-15, Volume: 27, Issue:4
Design, synthesis and identification of novel coumaperine derivatives for inhibition of human 5-LOX: Antioxidant, pseudoperoxidase and docking studies.
AID1253310Antiosteoclast activity in mouse BMM cells assessed as reduction of RANKL-induced osteoclasts differentiation by measuring TRAP positive multinucleated cells after 4 days by light microscopy2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
5-Lipoxygenase inhibitors suppress RANKL-induced osteoclast formation via NFATc1 expression.
AID1244232Inhibition of 5-LOX in human neutrophils assessed as reduction in LTB4 and 5-H(P)ETE) formation pre-incubated for 15 mins before A23187 and arachidonic acid substrate addition by RP-HPLC method2015European journal of medicinal chemistry, Aug-28, Volume: 101Design, synthesis and evaluation of semi-synthetic triazole-containing caffeic acid analogues as 5-lipoxygenase inhibitors.
AID74054Ability to inhibit histamine phase of antigen-induced bronchoconstriction in vivo in pulmonary function assays in which Guinea pigs were dosed orally 5 hours prior to test at 10 uM/kg; Not active1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application i
AID1427904Anti-inflammatory activity in CD-1 mouse model of Zymosan-induced peritonitis assessed as LTC4 level in peritoneal lavage at 10 mg/kg, ip pretreated for 30 mins followed by Zymosan injection measured after 30 mins by EIA (Rvb = 10.48 +/- 1.72 ng/ml)2017European journal of medicinal chemistry, Feb-15, Volume: 127Optimization of benzoquinone and hydroquinone derivatives as potent inhibitors of human 5-lipoxygenase.
AID160514Compound was tested for in vitro inhibition on human PMNL.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID372022Inhibition of human recombinant 5-lipoxygenase expressed in Escherichia coli assessed as 5LO product formation by cell free assay2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase.
AID625293Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID176569Ex vivo potency in rat blood for eicosanoid generation 1 hr after peroral administration1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1858311Anti-inflammatory activity against OVA-sensitized asthmatic BALB/c mouse model assessed as reduction in LTC4 level in lungs at 35 mg/kg, ip administered 30 mins prior to OVA challenge on days 0 and 7 and measured on day 21 by ELISA
AID1333419Cytotoxicity against human HeLa cells assessed as cell proliferation at 50 uM after 24 hrs by MTT assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Inhibition of the enzymes in the leukotriene and prostaglandin pathways in inflammation by 3-aryl isocoumarins.
AID1858285Inhibition of human recombinant 5-LOX expressed in Escherichia coli BL21(DE3) assessed as enzyme residual activity at 3 uM using arachidonic acid as substrate preincubated with enzyme for 15 mins followed by substrate addition and measured after 10 mins b
AID1858309Anti-inflammatory activity against OVA-sensitized asthmatic BALB/c mouse model assessed as inhibition of salbutamol-induced bronchial relaxation at 35 mg/kg, ip administered 30 mins prior to OVA challenge on days 0 and 7 and measured on day 21
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1406148Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using p-tyramine as substrate pretreated for 15 mins followed by substrate addition by horse-radish peroxidase/amplex red-based fluorescence method2018European journal of medicinal chemistry, Aug-05, Volume: 156Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
AID736008Inhibition of human recombinant soluble epoxide hydrolase expressed in Escherichia coli using 3-phenyl-cyano(6-methoxy-2-naphthalenyl)methylester-2-oxiraneacetic acid as substrate after 30 mins by fluorescence-based assay2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Synthesis and structure-activity relationship studies of novel dual inhibitors of soluble epoxide hydrolase and 5-lipoxygenase.
AID488204Selectivity ratio of IC50 for COX2-mediated 12-hydroxyheptadecatrienoic acid production in human whole blood to IC50 for COX1-mediated 12-hydroxyheptadecatrienoic acid production in human whole blood2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Synthesis and biological activity of N-aroyl-tetrahydro-gamma-carbolines.
AID77378Oral effective dose against antigen induced bronchoconstriction in the guinea pig1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1424044Inhibition of human recombinant COX2 assessed as reduction in PGE2 formation pre-incubated for 5 mins before arachidonic acid addition and measured after 20 mins by ELISA2017Journal of natural products, 04-28, Volume: 80, Issue:4
Anti-inflammatory Activity of Natural Geranylated Flavonoids: Cyclooxygenase and Lipoxygenase Inhibitory Properties and Proteomic Analysis.
AID101304Ex vivo inhibition of LTB-4 determined by measurement of A-23187-stimulated LTB-4 production in dog blood at 1 mg/kg po1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors.
AID132484In vitro inhibition of PGE-2 synthesis in plasma free mouse macrophages.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
(Methoxyalkyl)thiazoles: a new series of potent, selective, and orally active 5-lipoxygenase inhibitors displaying high enantioselectivity.
AID1587930Inhibition of LPS/IFNgamma-stimulated lipid peroxidation in mouse RAW264.7 cells at 5 uM after 24 hrs by BODIPY 581/591 C11-staining based FACS assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Novel 15-Lipoxygenase-1 Inhibitor Protects Macrophages from Lipopolysaccharide-Induced Cytotoxicity.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID212789In vitro inhibition of thromboxane B2 in human whole blood Value1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors.
AID1057869Inhibition of calcium ionophore (A23187)-stimulated human 5-LO assessed as reduction of 12(S)-HETE production by measuring remaining activity at 5 uM preincubated for 15 mins followed by calcium ionophore (A23187) addition measured after 15 mins by LC-MS/2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Synthesis and pharmacological characterization of benzenesulfonamides as dual species inhibitors of human and murine mPGES-1.
AID1484242Inhibition of 5-LO in human peripheral blood neutrophils using arachidonic acid as substrate preincubated for 15 mins followed by substrate addition measured after 10 mins in presence of Ca2+ ionophore A23187 by RP-HPLC analysis2017Journal of natural products, 03-24, Volume: 80, Issue:3
Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones.
AID1614266Inhibition of recombinant human 5-LOX expressed in Escherichia coli at 20 uM using arachidonic acid as substrate by UV-vis spectrophotometric method relative to control2019Bioorganic & medicinal chemistry, 02-15, Volume: 27, Issue:4
Design, synthesis and identification of novel coumaperine derivatives for inhibition of human 5-LOX: Antioxidant, pseudoperoxidase and docking studies.
AID1333390Inhibition of human recombinant 5-LOX pseudoperoxidase activity expressed in Escherichia coli BL21 assessed as 13(S)-HPODE consumption by measuring decrease in absorbance at 10 uM2016European journal of medicinal chemistry, Nov-29, Volume: 124Inhibition of the enzymes in the leukotriene and prostaglandin pathways in inflammation by 3-aryl isocoumarins.
AID775834Inhibition of human recombinant MMP-2 using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2.AcOH as substrate at 10 uM preincubated for 30 mins prior to substrate addition measured for 30 mins by fluorescence assay relative to control2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Investigating the selectivity of metalloenzyme inhibitors.
AID1736439Inhibition of human 5-Lipoxygenase using H2DCFDA as substrate preincubated for 5 mins and measured by Spectrophotometric assay2020European journal of medicinal chemistry, Mar-15, Volume: 190Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties.
AID1484244Anti inflammatory activity in CD-1 mouse assessed as reduction in zymosan-induced PGE2 by measuring PGE2 level in peritoneal exudates at 10 mg/kg, ip preincubated for 30 mins followed by zymosan addition measured after 30 mins by enzyme immunoassay (Rvb =2017Journal of natural products, 03-24, Volume: 80, Issue:3
Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones.
AID404479Inhibition of LTB4 production in mouse MC9 cells2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib.
AID1327133Inhibition of recombinant human 5-LO expressed in Escherichia coli BL21 at 3 uM using arachidonic acid as substrate preincubated for 15 mins followed by substrate addition measured after 10 mins by RP-HPLC analysis relative to control2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and biological evaluation of C(5)-substituted derivatives of leukotriene biosynthesis inhibitor BRP-7.
AID132518Compound was tested to inhibit Leukotriene formation in A-23187-stimulated human whole blood using LTB4 specific RIA in vitro1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.
AID1067164Inhibition of 5-LOX (unknown origin) using arachidonic acid as substrate after 5 mins by EIA2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Lead modification: amino acid appended indoles as highly effective 5-LOX inhibitors.
AID1139551Inhibition of human recombinant 5-LO assessed as product formation at 3 uM by cell-free assay relative to control2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase.
AID1333402Antioxidant activity assessed as DPPH radical scavenging activity at 50 uM after 30 mins2016European journal of medicinal chemistry, Nov-29, Volume: 124Inhibition of the enzymes in the leukotriene and prostaglandin pathways in inflammation by 3-aryl isocoumarins.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID128186Compound was tested for in vivo inhibition on mouse AA ear edema.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID1406022Anti-inflammatory activity in carrageenan-induced ICR mouse model of inflammation assessed as reduction in paw edema at 20 mg/kg, ip administered 30 mins prior to carrageenan challenge measured at 2 to 6 hrs post carrageenan challenge by plethysmometric m2018European journal of medicinal chemistry, Jul-15, Volume: 155Structural insight into the optimization of ethyl 5-hydroxybenzo[g]indol-3-carboxylates and their bioisosteric analogues as 5-LO/m-PGES-1 dual inhibitors able to suppress inflammation.
AID1614268Inhibition of human 5-LOX using arachidonic acid as substrate measured after 10 mins by ELISA2019Bioorganic & medicinal chemistry, 02-15, Volume: 27, Issue:4
Design, synthesis and identification of novel coumaperine derivatives for inhibition of human 5-LOX: Antioxidant, pseudoperoxidase and docking studies.
AID26809Calculated partition coefficient, excluding hydroxyurea fragment (clogP)1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.
AID1057565Inhibition of mPGES-1 from human A549 cell microsomal membranes using PGH2 as substrate incubated 15 mins prior to substrate addition measured after 1 min by RP-HPLC analysis2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo.
AID155904Compound was evaluated for the inhibition of,PLA2.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis, chemical, and biological properties of vinylogous hydroxamic acids: dual inhibitors of 5-lipoxygenase and IL-1 biosynthesis.
AID176568Ex vivo potency in for eicosanoid generation in inflammatory exudate of rat 3 hr after peroral administration1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors.
AID713974Inhibition of 5-LOX2012Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16
Anacardic acid derived salicylates are inhibitors or activators of lipoxygenases.
AID1126817Inhibition of human 5-LOX using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition by H2DCFDA staining-based fluorometric analysis2014Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8
Development of 3,5-dinitrobenzoate-based 5-lipoxygenase inhibitors.
AID1478501Inhibition of human recombinant 5-lipoxygenase expressed in Escherichia coli MV1190 pre-incubated for 10 mins before arachidonic acid substrate addition and measured after 10 mins by RP-HPLC method
AID717844Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID7094The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase1992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Development of 2,3-dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase.
AID1424046Selectivity index, ratio of IC50 for ram seminal vesicle COX1 to IC50 for human recombinant COX22017Journal of natural products, 04-28, Volume: 80, Issue:4
Anti-inflammatory Activity of Natural Geranylated Flavonoids: Cyclooxygenase and Lipoxygenase Inhibitory Properties and Proteomic Analysis.
AID1406531Antiinflammatory activity in zymosan induced CD-1 mouse model of inflammation assessed as reduction in leukocyte recruitment in air pouch at 10 mg/kg, ip preincubated for 30 mins followed by zymosan challenge and measured after 4 hrs by trypan blue staini2018European journal of medicinal chemistry, Aug-05, Volume: 156Discovery of a benzenesulfonamide-based dual inhibitor of microsomal prostaglandin E
AID1461599Inhibition of human COX-2 preincubated for 5 mins followed by arachidonic acid substrate addition by colorimetric enzyme immunoassay2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity.
AID1406495Inhibition of mPGES-1 isolated from microsomes of interleukin-1 beta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis2018European journal of medicinal chemistry, Aug-05, Volume: 156Discovery of a benzenesulfonamide-based dual inhibitor of microsomal prostaglandin E
AID102477Inhibitory activity against Leukotriene B4 receptor in human PMN1992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Development of 2,3-dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase.
AID1614270Inhibition of recombinant human 5-LOX pseudoperoxidase activity expressed in Escherichia coli BL21 assessed as compound redox activity by measuring reduction in absorption at 10 uM using 13(S)-HpODE as substrate by UV-vis spectrophotometric method relativ2019Bioorganic & medicinal chemistry, 02-15, Volume: 27, Issue:4
Design, synthesis and identification of novel coumaperine derivatives for inhibition of human 5-LOX: Antioxidant, pseudoperoxidase and docking studies.
AID296189Lipophilicity, log K of the compound2007European journal of medicinal chemistry, Aug, Volume: 42, Issue:8
Antileukotrienic N-arylethyl-2-arylacetamides in the treatment of ulcerative colitis.
AID775831Inhibition of HDAC2 (unknown origin)-mediated deacetylation at 10 uM preincubated for 5 mins prior to substrate addition measured after 30 mins by fluorescence assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Investigating the selectivity of metalloenzyme inhibitors.
AID1307675Inhibition of 5-LOX in human whole blood assessed as LTB4 production at 2 uM pre-incubated for 20 mins before stimulation with LPS and A23187 for 120 mins by LC-MS/MS method2016Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
Discovery of Novel 15-Lipoxygenase Activators To Shift the Human Arachidonic Acid Metabolic Network toward Inflammation Resolution.
AID76778Compound was tested for in vivo inhibition on gp AA bronchospasm.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID7065Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.
AID1676601Binding affinity to Zinc ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1569920Inhibition of soyabean 15-LOX preincubated for 5 mins followed by susbtrate addition measured after 10 mins by colorimetric method
AID1420840Inhibition of recombinant human 5-LOX expressed in Escherichia coli BL21 at 10 uM using arachidonic acid as substrate by UV-vis spectrophotometric method relative to control2018European journal of medicinal chemistry, Oct-05, Volume: 158Design, synthesis and identification of novel substituted 2-amino thiazole analogues as potential anti-inflammatory agents targeting 5-lipoxygenase.
AID178506Compound was tested for in vivo inhibition on rat peritoneal anaphylaxis.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID6911Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
AID1777267Antiinflammatory activity in zymosan-induced CD-1 mouse peritonitis model assessed as reduction in LTC4 level at 3 mg/kg, po preincubated with compound for 60 mins followed by zymosan addition and measured after 30 mins by ELISA2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Exploration of Long-Chain Vitamin E Metabolites for the Discovery of a Highly Potent, Orally Effective, and Metabolically Stable 5-LOX Inhibitor that Limits Inflammation.
AID160511Compound was evaluated for production of leukotriene B4 in Ca+2 -ionophore -activated human polymorphonuclear (HPMN) leukocytes.1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010.
AID1287591Inhibition of FLAP in Ca+2 ionophore A23187 stimulated human neutrophils assessed as 5-LO product formation preincubated for 15 mins measured after 10 mins by RP-HPLC analysis2016European journal of medicinal chemistry, May-04, Volume: 1134,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP).
AID78100In vivo activity in the leukotriene-dependent phase of allergen-induced bronchoconstriction in Guinea pigs total pulmonary resistance(RL) measured as percent inhibition at 50 micro mol/kg per os after 8 hours1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application i
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1676589Binding affinity to Nickel cation assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID754976Inhibition of N-terminal His6-tagged human platelet 12-LOX pseudoperoxidase activity assessed as reduction of active ferric ion to inactive ferrous state measured decomposition of 13-(S)-HPODE at 40 uM after 30 mins by iron-xylenol orange staining assay2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases.
AID6915Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
AID1143906Inhibition of human recombinant 5-LO expressed in Escherichia coli BL21 assessed as remaining activity using arachidonic acid as substrate preincubated at 10 uM for 5 to 10 mins by HPLC analysis2014European journal of medicinal chemistry, Jun-23, Volume: 81Further studies on ethyl 5-hydroxy-indole-3-carboxylate scaffold: design, synthesis and evaluation of 2-phenylthiomethyl-indole derivatives as efficient inhibitors of human 5-lipoxygenase.
AID1570239Cytoprotective activity against hypoxia-induced apoptosis in rat H9c2 cells assessed as early apoptotic cells at 2 uM preincubated for 18 hrs followed by incubated in hypoxia for 48 hrs by annexin V based flow cytometry2019European journal of medicinal chemistry, Oct-15, Volume: 180Protective effect of piceatannol and bioactive stilbene derivatives against hypoxia-induced toxicity in H9c2 cardiomyocytes and structural elucidation as 5-LOX inhibitors.
AID461096Inhibition of potato tuber 5LOX by polarographic method2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1676596Binding affinity to Ferric ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID730632Inhibition of 5LOX (unknown origin) using arachidonic acid as substrate after 5 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
N-1, C-3 substituted indoles as 5-LOX inhibitors--in vitro enzyme immunoaasay, mass spectral and molecular docking investigations.
AID1406530Antiinflammatory activity in zymosan induced CD-1 mouse model of inflammation assessed as reduction in LTB4 levels in air pouch at 10 mg/kg, ip preincubated for 30 mins followed by zymosan challenge and measured after 4 hrs by ELISA2018European journal of medicinal chemistry, Aug-05, Volume: 156Discovery of a benzenesulfonamide-based dual inhibitor of microsomal prostaglandin E
AID1411791Inhibition of rat 5-LOX expressed in Sf21 insect cells preincubated for 4 mins followed by AA substrate addition and measured after 4 mins by FOX assay2018MedChemComm, Feb-01, Volume: 9, Issue:2
Recent development of lipoxygenase inhibitors as anti-inflammatory agents.
AID3622Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis, chemical, and biological properties of vinylogous hydroxamic acids: dual inhibitors of 5-lipoxygenase and IL-1 biosynthesis.
AID92726Compound was tested for in vitro inhibition on human whole blood.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID176426Oral effective dose against LTB4 biosynthesis in the rat RPAR pleurisy model1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase.
AID89434Compound was evaluated for the inhibition of,IL-1beta biosynthesis.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis, chemical, and biological properties of vinylogous hydroxamic acids: dual inhibitors of 5-lipoxygenase and IL-1 biosynthesis.
AID6930Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1406151Antioxidant activity assessed as trolox equivalent of AAPH-induced radical scavenging activity pretreated for 15 mins followed by APPH challenge measured every minute for 80 mins by ORAC-FL assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
AID1139555Inhibition of 5-LO in human neutrophils assessed as product formation by cell-intact assay relative to control in presence of 20 uM A23187/AA ionophore2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase.
AID1226813Inhibition of soyabean 5-LOX using arachidonic acid as substrate by microplate scanning spectrophotometer analysis2015European journal of medicinal chemistry, Jun-05, Volume: 97Indole based peptidomimetics as anti-inflammatory and anti-hyperalgesic agents: Dual inhibition of 5-LOX and COX-2 enzymes.
AID1512367Inhibition of human recombinant 5-LOX expressed in Escherichia coli BL21 assessed as conversion of arachidonic acid to 5-HPETE using arachidonic acid as substrate in presence of ATP by UV-vis spectrophotometry analysis2019ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10
Chalcone-Thiazole Hybrids: Rational Design, Synthesis, and Lead Identification against 5-Lipoxygenase.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1858310Anti-inflammatory activity against OVA-sensitized asthmatic BALB/c mouse model assessed as reduction in bronchial epithelium thickness at 35 mg/kg, ip administered 30 mins prior to OVA challenge on days 0 and 7 and measured on day 21 by Hematoxylin and eo
AID6917Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
AID1268103Inhibition of 5-LOX in Sprague-Dawley rat leukocytes assessed as A23187 stimulated LTB4 production pretreated for 30 mins followed by addition of A23187 for 30 mins by EIA2016European journal of medicinal chemistry, Jan-27, Volume: 108Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1241830Anti-inflammatory activity in rat assessed as inhibition of arachidonic acid-induced paw edema at 10 mg/kg, po dosed 30 mins before arachidonic acid injection and measured 1 hr after arachidonic acid injection2015European journal of medicinal chemistry, Aug-28, Volume: 101Synthesis, characterization, evaluation and molecular dynamics studies of 5, 6-diphenyl-1,2,4-triazin-3(2H)-one derivatives bearing 5-substituted 1,3,4-oxadiazole as potential anti-inflammatory and analgesic agents.
AID241982Inhibitory concentration against human 5-lipoxygenase2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1854725Inhibition of soybean 5-LOX2022European journal of medicinal chemistry, Nov-05, Volume: 241Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
AID1656999Substrate activity at UDP-glucuronosyltransferase in cynomolgus monkey microsomes assessed as Vmax2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Acetylene Group, Friend or Foe in Medicinal Chemistry.
AID456268Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Inhibitory activity of Brazilian green propolis components and their derivatives on the release of cys-leukotrienes.
AID239062Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells; not tested2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.
AID754974Inhibition of N-terminal His6-tagged human prostate epithelial 15-LOX2 pseudoperoxidase activity assessed as reduction of active ferric ion to inactive ferrous state measured decomposition of 13-(S)-HPODE at 40 uM after 30 mins by iron-xylenol orange stai2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases.
AID1287590Inhibition of FLAP in Ca+2 ionophore A23187 stimulated human neutrophils assessed as remaining 5-LO activity preincubated for 15 mins at 10 uM measured after 10 mins by RP-HPLC analysis2016European journal of medicinal chemistry, May-04, Volume: 1134,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP).
AID6787Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
(+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist.
AID1717041Inhibition of recombinant human 5LOX expressed in baculovirus infected Sf insect cells using linoleic acid as substrate preincubated for 5 mins followed by substrate addition2020European journal of medicinal chemistry, Jan-15, Volume: 186Design, synthesis, in-vitro, in-vivo and in-silico studies of pyrrolidine-2,5-dione derivatives as multitarget anti-inflammatory agents.
AID669535Inhibition of 5-lipoxygenase/FLAP in calcium ionophore-stimulated human whole blood assessed as residual (+/-)11HETE level at 5 uM preincubated for 15 mins prior to calcium ionophore-stimulation measured after 15 mins by LC-MS/MS analysis2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
Structure-activity relationship of nonacidic quinazolinone inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1).
AID67735-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Synthesis and antiinflammatory activity of certain 5,6,7,8-tetrahydroquinolines and related compounds.
AID775832Inhibition of human carbonic anhydrase 2 assessed as p-nitrophenyl acetate conversion to p-nitrophenolate anion at 10 uM preincubated for 10 mins prior to substrate addition measured for 20 mins by spectrophotometric analysis relative to control2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Investigating the selectivity of metalloenzyme inhibitors.
AID1615198Antioxidant activity assessed as DPPH radical scavenging activity incubated for 30 mins under dark condition2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery of a novel 2,5-dihydroxycinnamic acid-based 5-lipoxygenase inhibitor that induces apoptosis and may impair autophagic flux in RCC4 renal cancer cells.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1073063Inhibition of human recombinant 5-lipoxygenase using arachidonic acid as substrate preincubated for 10 mins before substrate addition measured after 10 mins by HPLC analysis2014Journal of natural products, Mar-28, Volume: 77, Issue:3
One-step semisynthesis of oleacein and the determination as a 5-lipoxygenase inhibitor.
AID1201312Inhibition of 5-LOX in A23187-stimulated human blood PMNL assessed as reduction in lipoxygenase products formation in presence of arachidonic acid pre-incubated for 15 mins followed by stimulation with A23187 for 10 mins by RP-HPLC based cell based assay2015European journal of medicinal chemistry, Apr-13, Volume: 94Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.
AID176664Compound was evaluated ex vivo for inhibition of LTB4 synthesis in rat on oral administration.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
(Methoxyalkyl)thiazoles: a new series of potent, selective, and orally active 5-lipoxygenase inhibitors displaying high enantioselectivity.
AID179051In vitro inhibition of LTB4 synthesis in rat whole blood.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
(Methoxyalkyl)thiazoles: a new series of potent, selective, and orally active 5-lipoxygenase inhibitors displaying high enantioselectivity.
AID1174555Cytotoxicity against human U937 cells at 100 uM after 48 hrs by LDH assay2015European journal of medicinal chemistry, Jan-07, Volume: 89Development and evaluation of ST-1829 based on 5-benzylidene-2-phenylthiazolones as promising agent for anti-leukotriene therapy.
AID698653Inhibition of 5-LOX in stimulated leukocytes2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Dynamic modeling of human 5-lipoxygenase-inhibitor interactions helps to discover novel inhibitors.
AID296191Displacement of [3H]LTB4 from LTB4 receptor in guinea pig spleen membrane2007European journal of medicinal chemistry, Aug, Volume: 42, Issue:8
Antileukotrienic N-arylethyl-2-arylacetamides in the treatment of ulcerative colitis.
AID1304630Inhibition of 5-LO in human polymorphonuclear leukocytes assessed as residual activity at 1 uM preincubated for 10 mins followed by addition of arachidonic acid as substrate measured after 10 mins by HPLC method relative to control2016Journal of natural products, Mar-25, Volume: 79, Issue:3
Humudifucol and Bioactive Prenylated Polyphenols from Hops (Humulus lupulus cv. "Cascade").
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID6896Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
AID1065370Inhibition of human recombinant 5-LO expressed in Escherichia coli BL21 using arachidonic acid as substrate after 10 mins2013European journal of medicinal chemistry, Sep, Volume: 67Discovery and biological evaluation of novel 1,4-benzoquinone and related resorcinol derivatives that inhibit 5-lipoxygenase.
AID155820Effect on production of LTB4 in human polymorphonuclear (HPMN) leukocytes1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Thiopyrano[2,3,4-cd]indoles as 5-lipoxygenase inhibitors: synthesis, biological profile, and resolution of 2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5 -dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acid.
AID733340Inhibition of 5-LOX (unknown origin) at 10 uM by cell-free assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery of highly potent microsomal prostaglandin e2 synthase 1 inhibitors using the active conformation structural model and virtual screen.
AID1461597Gastrointestinal toxicity in adjuvant-induced Wistar rat arthritis model assessed as ulcer index treated for 7 days measured on day 21 post arthritis induction2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity.
AID161677The compound was evaluated for its inhibitory activity against Prostaglandin G/H synthase 1 using monocytes-like cells2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor.
AID90241Glucuronidation rates in human liver microsomes1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.
AID475089Inhibition of 5-LOX-mediated LTB4 production in stimulated human neutrophile granulocytes after 10 mins by EIA2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Derivatives of schisandrin with increased inhibitory potential on prostaglandin E(2) and leukotriene B(4) formation in vitro.
AID1512366Inhibition of human recombinant 5-LOX expressed in Escherichia coli BL21 assessed as conversion of arachidonic acid to 5-HPETE at 10 uM using arachidonic acid as substrate in presence of ATP by UV-vis spectrophotometry analysis relative to control2019ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10
Chalcone-Thiazole Hybrids: Rational Design, Synthesis, and Lead Identification against 5-Lipoxygenase.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID155822In vitro inhibition of LTB4 formation in human peripheral blood polymorphonuclear leukocytes (HPMN)1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids.
AID138599Percent inhibition was determined at a dose of 10 mg/Kg in mouse ex vivo assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Structure-activity relationship studies on 1-[2-(4-Phenylphenoxy)ethyl]pyrrolidine (SC-22716), a potent inhibitor of leukotriene A(4) (LTA(4)) hydrolase.
AID1676593Binding affinity to Gallium ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1443721Inhibition of 15-LOX in human primary polymorphonuclear leukocytes2017Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8
Easy and rapid preparation of benzoylhydrazides and their diazene derivatives as inhibitors of 15-lipoxygenase.
AID6905Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
AID1579859Inhibition of LTC4S in healthy human whole blood assessed as inhibition of calcium ionophore A23187 stimulated cysteinyl leukotrienes production preincuabted for 30 mins followed by calcium ionophore stimulation and measured after 10 mins by LC-MS analysi2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1
AID6707In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.
AID1152197Inhibition of human 5-LOX using arachidonic acid as substrate measured as H2DCFDA conversion to 2',7'-dichlorofluorescein preincubated for 10 mins by fluorescence spectrophotometric analysis2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Benzo[d]isothiazole 1,1-dioxide derivatives as dual functional inhibitors of 5-lipoxygenase and microsomal prostaglandin E(2) synthase-1.
AID488203Inhibition of COX2 in human whole blood assessed as inhibition of 12-hydroxyheptadecatrienoic acid production by HPLC method2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Synthesis and biological activity of N-aroyl-tetrahydro-gamma-carbolines.
AID1139553Inhibition of human recombinant 5-LO assessed as product formation by cell-free assay relative to control2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase.
AID1587931Protection against LPS-induced cell death in mouse RAW264.7 cells assessed as increase in cell viability at 5 uM measured after 48 hrs by MTS assay relative to control2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Novel 15-Lipoxygenase-1 Inhibitor Protects Macrophages from Lipopolysaccharide-Induced Cytotoxicity.
AID1653794Substrate activity at human mARC1 expressed in Escherichia coli assessed as turnover rates at 1 mM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by UV-Visible spectroscopy based NADH assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID1307677Inhibition of 5-LOX in human whole blood assessed as increase in PGE2 production at 2 uM pre-incubated for 20 mins before stimulation with LPS and A23187 for 120 mins by LC-MS/MS method2016Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
Discovery of Novel 15-Lipoxygenase Activators To Shift the Human Arachidonic Acid Metabolic Network toward Inflammation Resolution.
AID1653799Substrate activity at human mARC2 expressed in Escherichia coli assessed as turnover rates at 1 mM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by UV-Visible spectroscopy based NADH assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID1617774Inhibition of human recombinant 5-LOX expressed in insect cells assessed as decrease in production of 5-HPETE and 5-HETE using arachidonic acid as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by ferric io2019Journal of natural products, 12-27, Volume: 82, Issue:12
Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID92731Compound was tested for the inhibition of LTB4 production in human whole blood (HWB)1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID92880Inhibition of 5-lipoxygenase (5-LO) measured as LTB4 production in human whole blood stimulated with calcium ionophore (A23187).1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1065368Inhibition of 5-LO in human PMNL using arachidonic acid as substrate preincubated for 15 mins2013European journal of medicinal chemistry, Sep, Volume: 67Discovery and biological evaluation of novel 1,4-benzoquinone and related resorcinol derivatives that inhibit 5-lipoxygenase.
AID1488612Inhibition of 5-LOX in Sprague Dawley rat Leukocytes assessed as reduction in calcium ionophore A23187-induced LTB4 production preincubated for 30 mins followed by calcium ionophore A23187 addition measured after 30 mins by ELISA2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Synthesis of novel hybrids of pyrazole and coumarin as dual inhibitors of COX-2 and 5-LOX.
AID1858314Anti-inflammatory activity against OVA-sensitized asthmatic BALB/c mouse model assessed as effect on OVA-sensitization by measuring IL-4 levels in lungs at 35 mg/kg, ip administered 30 mins prior to OVA challenge on days 0 and 7 and measured on day 21 by
AID176565Ex vivo oral effective dose against LTB4 biosynthesis in rat blood, after pretreatment period of 3h1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase.
AID1307676Inhibition of 5-LOX in human whole blood assessed as increase in TXB2 production at 2 uM pre-incubated for 20 mins before stimulation with LPS and A23187 for 120 mins by LC-MS/MS method2016Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
Discovery of Novel 15-Lipoxygenase Activators To Shift the Human Arachidonic Acid Metabolic Network toward Inflammation Resolution.
AID1057871Inhibition of calcium ionophore (A23187)-stimulated human 5-LO assessed as reduction of 5(S)-HETE production by measuring remaining activity at 5 uM preincubated for 15 mins by followed by calcium ionophore (A23187) addition measured after 15 mins by LC-M2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Synthesis and pharmacological characterization of benzenesulfonamides as dual species inhibitors of human and murine mPGES-1.
AID661902Inhibition of 5-lipoxygenase in human polynuclear leukocytes assessed as inhibition of A23187-stimulated 5-LO product formation preincubated for 15 mins measured after 10 mins by HPLC analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and biological evaluation of a class of 5-benzylidene-2-phenyl-thiazolinones as potent 5-lipoxygenase inhibitors.
AID76779Compound was tested for in vivo inhibition on gp antigen bronchospasm.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID775829Inhibition of mushroom tyrosinase assessed as L-DOPA conversion to melanin at 10 uM preincubated for 10 mins prior to substrate addition measured after 10 mins by spectrophotometric analysis2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Investigating the selectivity of metalloenzyme inhibitors.
AID296192Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced oedema at 100 mg/kg by Winter method2007European journal of medicinal chemistry, Aug, Volume: 42, Issue:8
Antileukotrienic N-arylethyl-2-arylacetamides in the treatment of ulcerative colitis.
AID1403474Inhibition of soybean 15-LOX using linoleic acid as substrate by colorimetric method2018European journal of medicinal chemistry, Jan-20, Volume: 144Novel click modifiable thioquinazolinones as anti-inflammatory agents: Design, synthesis, biological evaluation and docking study.
AID161185Inhibitory concentration against sheep seminal vesicle Prostaglandin G/H synthase1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors.
AID1653804Substrate activity at human mARC1 expressed in Escherichia coli assessed as turnover rates at 1 mM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by LC-MS analysis based assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID6706In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors.
AID132483In vitro inhibition of LTC4 synthesis in plasma free mouse macrophages.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
(Methoxyalkyl)thiazoles: a new series of potent, selective, and orally active 5-lipoxygenase inhibitors displaying high enantioselectivity.
AID650765Inhibition of 5-lipoxygenase2012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
SAR-study on a new class of imidazo[1,2-a]pyridine-based inhibitors of 5-lipoxygenase.
AID345897Inhibition of IgE-specific antigen-induced LBT4 release in rat MC9 cells at 0.55 uM2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors.
AID197719The plasma levels measured after one hour after 200 (micro mol/Kg) oral dose in rat.1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.
AID78103In vivo activity in the leukotriene-dependent phase of allergen-induced bronchoconstriction in Guinea pigs total pulmonary resistance(RL) measured as percent inhibition at 50 micro mol/kg per os after 8 hours1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application i
AID127801In vivo 5-Lipoxygenase inhibitory activity by using mouse zymosan peritonitis model1992Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17
Benzothiazole hydroxy ureas as inhibitors of 5-lipoxygenase: use of the hydroxyurea moiety as a replacement for hydroxamic acid.
AID1569919Selectivity index, ratio of IC50 for ovine COX-1 to IC50 for human COX-2
AID1143907Inhibition of human recombinant 5-LO expressed in Escherichia coli BL21 using arachidonic acid as substrate preincubated for 5 to 10 mins by HPLC analysis2014European journal of medicinal chemistry, Jun-23, Volume: 81Further studies on ethyl 5-hydroxy-indole-3-carboxylate scaffold: design, synthesis and evaluation of 2-phenylthiomethyl-indole derivatives as efficient inhibitors of human 5-lipoxygenase.
AID372030Antiinflammatory activity against lambda carrageenan-induced pleurisy in Wistar Han rat assessed as reduction in exudate volume at 10 mg/kg, ip administered 30 mins before carrageenan challenge measured after 4 hrs by trypan blue staining2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase.
AID7096In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
4-hydroxythiazole inhibitors of 5-lipoxygenase.
AID1126818Inhibition of 5-LOX in human whole blood assessed as inhibition of A23187-induced LTB4 production preincubated for 15 mins followed by A23187 induction measured after 30 mins by ELISA2014Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8
Development of 3,5-dinitrobenzoate-based 5-lipoxygenase inhibitors.
AID1819014Inhibition of 5-LO in thapsigargin stimulated human PMNL cells assessed as reduction in 5-LO product level preincubated for 5 mins followed by thapsigargin addition and measured after 15 mins by RP-HPLC analysis2022Journal of natural products, 01-28, Volume: 85, Issue:1
Structure-Activity Relationship Studies of New Sinapic Acid Phenethyl Ester Analogues Targeting the Biosynthesis of 5-Lipoxygenase Products: The Role of Phenolic Moiety, Ester Function, and Bioisosterism.
AID1676598Binding affinity to cupric ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID92853In vitro inhibitory concentration against LTB4 biosynthesis in calcium ionophore-stimulated human whole blood leukocyte (HBL) assay1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID698652Inhibition of human recombinant 5-LOX expressed in Escherichia coli BL2-DE3 incubated 10 mins before substrate addition by fluorescence spectrophotometry based cell free system assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Dynamic modeling of human 5-lipoxygenase-inhibitor interactions helps to discover novel inhibitors.
AID1461766Inhibition of human recombinant 5-LO at 3 mM using arachidonic acid as substrate in presence of Ca2+ stimulating cofactor2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
Recent synthetic and medicinal perspectives of tryptanthrin.
AID6923Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
AID101298In vitro inhibition of ionophore stimulated LTB4 release from human peripheral blood leukocytes.1992Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17
Benzothiazole hydroxy ureas as inhibitors of 5-lipoxygenase: use of the hydroxyurea moiety as a replacement for hydroxamic acid.
AID92870Inhibitory activity of the compound against leukotriene (LT) B4 production in human whole blood1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase.
AID589217Mechanism based inhibition of human cytochrome P450 1A2 measured by phenacetin O-deethylation (POD) 2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID6949In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
AID775842Inhibition of 5-LOX (unknown origin)-mediated leukotriene (LT)B4 biosynthesis2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Investigating the selectivity of metalloenzyme inhibitors.
AID775833Inhibition of human recombinant MMP-12 using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2.AcOH as substrate at 10 uM preincubated for 30 mins prior to substrate addition measured for 30 mins by fluorescence assay relative to control2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Investigating the selectivity of metalloenzyme inhibitors.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID6901Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID24074t1/2 in monkey at after IV dose (20 umol/kg)1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.
AID632046Inhibition of FLAP in human whole blood assessed as inhibition of calcium ionophore A23187-induced LTB4 production preincubated for 15 mins by ELISA2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhib
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID346088Inhibition of IgE-specific antigen-induced PGF2-alpha release in rat MC9 cells2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID6909Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
AID688620Inhibition of 5-lipoxygenase in human neutrophils assessed as inhibition of LTB4 production2011Journal of natural products, Aug-26, Volume: 74, Issue:8
Lignan derivatives from Krameria lappacea roots inhibit acute inflammation in vivo and pro-inflammatory mediators in vitro.
AID6907Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
AID101301Duration of action where maximum inhibition of LTB4 formation is achieved at 1 mg/kg iv1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors.
AID1461596Anti inflammatory activity in arachidonic acid-induced Wistar rat paw edema model assessed as inhibition of right hind paw edema thickness at 10 mg/kg, po pretreated for 30 mins followed by arachidonic acid challenge measured after 1 hr (Rvb = 0%)2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID6913Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
AID1275235Antiinflammatory activity in ICR mouse assessed as reduction in carrageenan-induced paw oedema volume at 20 mg/kg, ip administered 30 mins before carrageenan challenge measured after 0 to 6 hrs by hydroplethysmometer2016European journal of medicinal chemistry, Jan-27, Volume: 108Exploring the role of chloro and methyl substitutions in 2-phenylthiomethyl-benzoindole derivatives for 5-LOX enzyme inhibition.
AID7057Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells1998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
Design, synthesis, and biological evaluation of conformationally constrained aci-reductone mimics of arachidonic acid.
AID1253309Inhibition of 5-LO in mouse BMM cells assessed as formation of LTC4 after 30 mins by enzyme immunoassay2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
5-Lipoxygenase inhibitors suppress RANKL-induced osteoclast formation via NFATc1 expression.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1065369Inhibition of 5-LO in human PMNL using arachidonic acid as substrate assessed as residual activity at 10 uM preincubated for 15 mins2013European journal of medicinal chemistry, Sep, Volume: 67Discovery and biological evaluation of novel 1,4-benzoquinone and related resorcinol derivatives that inhibit 5-lipoxygenase.
AID377036Ex vivo inhibition of leukotriene formation in calcium ionophore activated human neutrophilic granulocyte by ELISA2005Journal of natural products, Jan, Volume: 68, Issue:1
Inhibition of leukotriene biosynthesis by stilbenoids from Stemona species.
AID19124Phase 1 oral half life was determined1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1543288Inhibition of human recombinant 5-LOX assessed as reduction in leukotriene B4 synthesis using arachidonic acid substrate by ELISA2019Journal of natural products, 07-26, Volume: 82, Issue:7
Prenylated Stilbenoids Affect Inflammation by Inhibiting the NF-κB/AP-1 Signaling Pathway and Cyclooxygenases and Lipoxygenase.
AID296194Antiinflammatory activity in mouse assessed as inhibition of arachidonic acid-induced hyperaemia at 200 mg/kg, po2007European journal of medicinal chemistry, Aug, Volume: 42, Issue:8
Antileukotrienic N-arylethyl-2-arylacetamides in the treatment of ulcerative colitis.
AID69705-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4)1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.
AID1057566Inhibition of human recombinant 5-lipoxygenase expressed in Escherichia coli BL21 using arachidonic acid as substrate incubated 5 to 10 mins prior to substrate addition measured after 10 mins by HPLC analysis2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo.
AID1854723Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate and measured by fluorometric assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
AID1406145Inhibition of human 5-lipoxygenase using arachidonic acid as substrate pretreated for 10 mins followed by substrate and ATP addition and measured after 20 mins by H2DCFDA probe based fluorescence assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
AID669532Inhibition of 5-lipoxygenase/FLAP in calcium ionophore-stimulated human whole blood assessed as residual 5(s)HETE level at 5 uM preincubated for 15 mins prior to calcium ionophore-stimulation measured after 15 mins by LC-MS/MS analysis2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
Structure-activity relationship of nonacidic quinazolinone inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1).
AID6879Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors.
AID1484245Anti inflammatory in CD-1 mouse assessed as reduction in zymosan-induced inflammatory cell infiltration by measuring inflammatory cell level in peritoneal exudates at 10 mg/kg, ip preincubated for 30 mins followed by zymosan addition measured after 4 hrs 2017Journal of natural products, 03-24, Volume: 80, Issue:3
Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones.
AID1174553Cytotoxicity against human U937 cells assessed as cell viability at 100 uM after 48 hrs by WST-1 assay2015European journal of medicinal chemistry, Jan-07, Volume: 89Development and evaluation of ST-1829 based on 5-benzylidene-2-phenylthiazolones as promising agent for anti-leukotriene therapy.
AID6710Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors.
AID1424043Inhibition of ram seminal vesicle COX1 assessed as reduction in PGE2 formation pre-incubated for 5 mins before arachidonic acid addition and measured after 20 mins by ELISA2017Journal of natural products, 04-28, Volume: 80, Issue:4
Anti-inflammatory Activity of Natural Geranylated Flavonoids: Cyclooxygenase and Lipoxygenase Inhibitory Properties and Proteomic Analysis.
AID160868Inhibition of prostaglandin G/H synthase pathway in rat polymorphonuclear assay by ability to inhibit formation of TXB2 at 10 uM.1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Synthesis and antiinflammatory activity of certain 5,6,7,8-tetrahydroquinolines and related compounds.
AID1676592Binding affinity to Gallium ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1615194Inhibition of 5-LO in human PMNL cells assessed as reduction in leukotriene formation at 1 uM preincubated for 5 mins followed by thapsigargin stimulation measured after 15 mins by RP-HPLC analysis relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery of a novel 2,5-dihydroxycinnamic acid-based 5-lipoxygenase inhibitor that induces apoptosis and may impair autophagic flux in RCC4 renal cancer cells.
AID469010Inhibition of 5-LOX at 100 uM after 5 mins2009Journal of natural products, Oct, Volume: 72, Issue:10
Monoterpenoid indole alkaloids from Alstonia yunnanensis.
AID6732The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor.
AID1512369Inhibition of human recombinant 5-LOX pseudoperoxidase activity expressed in Escherichia coli BL21 assessed as compound redox activity by measuring change in absorption at 10 uM using 13(S)-HpODE as substrate in presence of ATP by UV-vis spectrophotometri2019ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10
Chalcone-Thiazole Hybrids: Rational Design, Synthesis, and Lead Identification against 5-Lipoxygenase.
AID6728Tested for activity against 5-lipoxygenase1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Thiopyrano[2,3,4-cd]indoles as 5-lipoxygenase inhibitors: synthesis, biological profile, and resolution of 2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5 -dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acid.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID104155In vitro inhibitory activity against 5-lipoxygenase by reduction of 5-hydroxyeicosatetraenoic acid (5-HETE) formed in guinea pig polymorphonuclear leukocytes (PMNs).1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors.
AID1065371Inhibition of human recombinant 5-LO expressed in Escherichia coli BL21 using arachidonic acid as substrate assessed as residual activity at 10 uM after 10 mins2013European journal of medicinal chemistry, Sep, Volume: 67Discovery and biological evaluation of novel 1,4-benzoquinone and related resorcinol derivatives that inhibit 5-lipoxygenase.
AID161851Selectivity as ratio of the inhibitory concentration values Prostaglandin G/H synthase 1 to Prostaglandin G/H synthase 2; ns means Non selective2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor.
AID126490Rate of glucuronidation was determined using a microsomal preparation from the monkey liver tissue1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.
AID1333391Inhibition of human recombinant 5-LOX expressed in Escherichia coli BL21 assessed as decrease in 5-HPETE production at 50 uM preincubated with enzyme followed by arachidonic acid substrate addition by UV-vis spectrophotometry2016European journal of medicinal chemistry, Nov-29, Volume: 124Inhibition of the enzymes in the leukotriene and prostaglandin pathways in inflammation by 3-aryl isocoumarins.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID6725Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.
AID3637The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-11992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID243422log (1/Km) value for human liver microsome cytochrome P450 3A42005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
AID1549679Inhibition of Sprague-Dawley rat 5-LOX assessed as calcium ionophore A23187-stimulated LTB4 production preincubated for 30 mins followed by calcium ionophore A23187 addition and measured after 30 mins by ELISA2019European journal of medicinal chemistry, May-01, Volume: 169Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2/5-LOX inhibitors and antitumor agents.
AID296188Partition coefficient, log P of the compound2007European journal of medicinal chemistry, Aug, Volume: 42, Issue:8
Antileukotrienic N-arylethyl-2-arylacetamides in the treatment of ulcerative colitis.
AID1201309Inhibition of human recombinant 5-LOX expressed in Escherichia coli BL21 incubated for 10 mins in presence of arachidonic acid by RP-HPLC based cell-free assay2015European journal of medicinal chemistry, Apr-13, Volume: 94Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.
AID1676587Inhibition of 5-Lipoxygenase (unknown origin)2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1608445Inhibition of 5-LOX (unknown origin)2019European journal of medicinal chemistry, Oct-15, Volume: 180Role of sulphur-heterocycles in medicinal chemistry: An update.
AID698651Inhibition of human 5-LOX in A23187-induced human whole blood assessed as reduction in LTB4 production pre-incubated for 20 mins before A23187 addition by enzyme immunoassay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Dynamic modeling of human 5-lipoxygenase-inhibitor interactions helps to discover novel inhibitors.
AID77253Intravenous effective dose against antigen induced bronchoconstriction in the guinea pig1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase.
AID78099In vivo activity in the leukotriene-dependent phase of allergen-induced bronchoconstriction in Guinea pigs total pulmonary resistance(RL) measured as percent inhibition at 50 micro mol/kg per os after 5 hours1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application i
AID1244230Inhibition of human 5-LOX expressed in Escherichia coli Bl21 (DE3) assessed as reduction in LTB4 and 5-H(P)ETE) formation pre-incubated for 10 mins before arachidonic acid substrate addition by RP-HPLC method2015European journal of medicinal chemistry, Aug-28, Volume: 101Design, synthesis and evaluation of semi-synthetic triazole-containing caffeic acid analogues as 5-lipoxygenase inhibitors.
AID1461600Inhibition of soybean lipoxygenase preincubated for 5 mins followed by linoleic acid substrate addition measured after 20 mins by spectrophotometric method2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity.
AID1676588Binding affinity to Zinc ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID92885Compound was evaluated for inhibiting production of LTB4 in calcium Ionophore (A23187) activated human whole blood.1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
(+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist.
AID176207In vivo inhibition of ionophore induced rat pleurisy.2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Heteroarylmethoxyphenylalkoxyiminoalkylcarboxylic acids as leukotriene biosynthesis inhibitors.
AID7069Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency.
AID1427906Anti-inflammatory activity in CD-1 mouse model of Zymosan-induced peritonitis assessed as inflammatory cells in peritoneal lavage at 10 mg/kg, ip pretreated for 30 mins followed by Zymosan injection measured after 4 hrs (Rvb = 7 +/- 0.47 10'6No_unit)2017European journal of medicinal chemistry, Feb-15, Volume: 127Optimization of benzoquinone and hydroquinone derivatives as potent inhibitors of human 5-lipoxygenase.
AID404462Inhibition of leukotrienes production in mouse MC9 cells2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1676591Binding affinity to Nickel cation assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1542244Inhibition of soya bean 15-LOX by colorimetric lipoxygenase inhibitor screening assay kit method2019European journal of medicinal chemistry, Apr-01, Volume: 167Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
AID632047Inhibition of FLAP in human whole blood assessed as inhibition of calcium ionophore A23187-induced LTB4 production preincubated for 5 hrs by ELISA2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhib
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID6694Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010.
AID372031Antiinflammatory activity against lambda carrageenan-induced pleurisy in Wistar Han rat assessed as reduction in cellular infiltration at 10 mg/kg, ip administered 30 mins before carrageenan challenge measured after 4 hrs by trypan blue staining2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase.
AID127383Compound was tested to inhibit Leukotriene formation in mouse sensitized with 1BD8 cells after 7 hr of compound administration, activity expressed as percent of control1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.
AID1569918Inhibition of human COX-2 using arachidonic acid as substrate incubated for 5 mins by fluorescence-based assay
AID162669The compound was evaluated for its inhibitory activity against Prostaglandin G/H synthase 2 using osteosarcomes cells2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor.
AID1512368Antioxidant activity assessed as DPPH radical scavenging activity at 10 uM after 30 mins under dark condition relative to control2019ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10
Chalcone-Thiazole Hybrids: Rational Design, Synthesis, and Lead Identification against 5-Lipoxygenase.
AID127379Inhibition of leukotriene formation in A-23187-stimulated mouse whole blood using LTB4 specific RIA ex vivo, activity expressed as percent of control.1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.
AID6878Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors.
AID620273Inhibition of 5-Lipoxygenase in arachidonic acid-stimulated human neutrophils after 15 mins by HPLC analysis in presence of A231872011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Pyrazol-3-propanoic acid derivatives as novel inhibitors of leukotriene biosynthesis in human neutrophils.
AID540235Phospholipidosis-negative literature compound
AID1307674Inhibition of 5-LOX in human whole blood assessed as 5-HETE production at 2 uM pre-incubated for 20 mins before stimulation with LPS and A23187 for 120 mins by LC-MS/MS method2016Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
Discovery of Novel 15-Lipoxygenase Activators To Shift the Human Arachidonic Acid Metabolic Network toward Inflammation Resolution.
AID166520Compound was tested for in vitro inhibition on broken RBL-1.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1858312Anti-inflammatory activity against OVA-sensitized asthmatic BALB/c mouse model assessed as effect on OVA-sensitization by measuring plasma IgE levels at 35 mg/kg, ip administered 30 mins prior to OVA challenge on days 0 and 7 and measured on day 21 by ELI
AID1406529Antiinflammatory activity in CD-1 mouse assessed as reduction in zymosan-induced LTC4 formation in peritoneal cavity at 10 mg/kg, ip preincubated for 30 mins followed by zymosan addition measured after 30 mins by ELISA2018European journal of medicinal chemistry, Aug-05, Volume: 156Discovery of a benzenesulfonamide-based dual inhibitor of microsomal prostaglandin E
AID1333401Inhibition of mPGES1 in human HeLa cells assessed as reduction in TNF-alpha induced PGE2 production at 50 uM preincubated for 2 hrs followed by TNF-alpha addition for 24 hrs by ELISA2016European journal of medicinal chemistry, Nov-29, Volume: 124Inhibition of the enzymes in the leukotriene and prostaglandin pathways in inflammation by 3-aryl isocoumarins.
AID1461764Inhibition of 5-LO in LPS-stimulated human neutrophils by HPLC analysis2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
Recent synthetic and medicinal perspectives of tryptanthrin.
AID669534Inhibition of 5-lipoxygenase/FLAP in calcium ionophore-stimulated human whole blood assessed as residual 15(s)HETE level at 5 uM preincubated for 15 mins prior to calcium ionophore-stimulation measured after 15 mins by LC-MS/MS analysis2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
Structure-activity relationship of nonacidic quinazolinone inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1).
AID177815Compound was evaluated in vivo for the rat anaphylaxis leukotriene formation at an oral dose of 30 umol/kg1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.
AID427632Inhibition of 5LOX-mediated LTB4 formation in stimulated human polymorphonuclear leukocytes2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxygenase-mediated LTB4-formation.
AID89122Inhibition of calcium ionophore (A-23187)-stimulated LTB4 formation in human neutrophil assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Heteroarylmethoxyphenylalkoxyiminoalkylcarboxylic acids as leukotriene biosynthesis inhibitors.
AID86594In vitro binding affinity towards histamine H1 receptor at 5 mg/kg2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.
AID1676600Binding affinity to zinc ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID346089Inhibition of arachidonic acid-induced PGF2-alpha release in rat MC9 cells2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors.
AID296190Antileukotrienic activity in rat polymorphonuclear cells assessed as inhibition of LTB4 biosynthesis2007European journal of medicinal chemistry, Aug, Volume: 42, Issue:8
Antileukotrienic N-arylethyl-2-arylacetamides in the treatment of ulcerative colitis.
AID1139554Inhibition of 5-LO in human neutrophils assessed as product formation by cell-intact assay relative to control in presence of 2.5 uM A23187 ionophore2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase.
AID1903438Binding affinity to immobilized Halo tag-fused CysLT receptor (unknown origin) expressed in Escherichia coli BL21 (DE3) assessed as retention time by chromatography
AID372032Antiinflammatory activity against lambda carrageenan-induced pleurisy in Wistar Han rat assessed as reduction in LTB4 level at 10 mg/kg, ip administered 30 mins before carrageenan challenge measured after 4 hrs by EIA2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase.
AID160715Compound was evaluated for the inhibition of Prostaglandin G/H synthase1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis, chemical, and biological properties of vinylogous hydroxamic acids: dual inhibitors of 5-lipoxygenase and IL-1 biosynthesis.
AID1537241Antiallergic activity in CD-1 mouse model of IgE/DNP-BSA-stimulated passive cutaneous anaphylaxis assessed as inhibition of vascular permeability at 5% administered topically immediately after sensitization by Evans blue extravasation assay2019Journal of natural products, 02-22, Volume: 82, Issue:2
In Vivo Anti-inflammatory and Antiallergic Activity of Pure Naringenin, Naringenin Chalcone, and Quercetin in Mice.
AID1703351Inhibition of recombinant human 5-LO expressed in Escherichia coli BL21(DE3) assessed as reduction in LTB4 and 5-H(P)ETE formation using arachidonic acid as substrate preincubated with enzyme for 10 mins followed by substrate addition and measured after 12020European journal of medicinal chemistry, Sep-15, Volume: 202Structure-based design, semi-synthesis and anti-inflammatory activity of tocotrienolic amides as 5-lipoxygenase inhibitors.
AID1287592Inhibition of recombinant human 5-LO expressed in Escherichia coli BL21 assessed as 5-LO product formation preincubated for 15 mins followed by addition of arachidonic acid as substrate measured after 10 mins by RP-HPLC analysis2016European journal of medicinal chemistry, May-04, Volume: 1134,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP).
AID74176Ability to inhibit histamine phase of platelet activating factor (PAF)-induced bronchoconstriction in vivo in pulmonary function assays in which Guinea pigs were dosed orally 5 hours prior to test; Not tested1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application i
AID1202853Inhibition of human recombinant 5-LOX expressed in Escherichia coli BL21 DE3 assessed as reduction in 5-LO product formation at 3 uM pre-incubated for 10 mins by RP-HPLC method2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Myxochelins target human 5-lipoxygenase.
AID6964Inhibitory activity uM1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application i
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1858286Inhibition of 5-LOX in human PMNL assessed as enzyme residual activity at 3 uM preincubated for 15 mins followed by A23187 addition and measured after 10 mins by RP-HPLC analysis
AID730631Binding affinity to 5LOX (unknown origin) by mass spectrophotometric analysis2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
N-1, C-3 substituted indoles as 5-LOX inhibitors--in vitro enzyme immunoaasay, mass spectral and molecular docking investigations.
AID138603Percentage inhibition of LTB4 after 6 hr at dose 2 mg/kg in mouse1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.
AID92720Compound was evaluated for production of leukotriene B4 in human whole blood (HWB) activated with ionophore A-23187.1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010.
AID1057567Inhibition of 5-lipoxygenase in A23187-stimulated human polymorphonuclear leukocytes using arachidonic acid as substrate incubated 15 mins prior to substrate addition measured after 10 mins by HPLC analysis2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1143900Inhibition of 5-LO in human polymorphonuclear leukocytes assessed as inhibition of LTB4 production from arachidonic acid preincubated for 15 mins by HPLC analysis2014European journal of medicinal chemistry, Jun-23, Volume: 81Further studies on ethyl 5-hydroxy-indole-3-carboxylate scaffold: design, synthesis and evaluation of 2-phenylthiomethyl-indole derivatives as efficient inhibitors of human 5-lipoxygenase.
AID104156In vitro inhibitory activity against 5-lipoxygenase by reduction of LTB4 formed in guinea pig polymorphonuclear leukocytes (PMNs).1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors.
AID1420841Antioxidant activity assessed as DPPH radical scavenging activity at 20 uM measured after 30 mins2018European journal of medicinal chemistry, Oct-05, Volume: 158Design, synthesis and identification of novel substituted 2-amino thiazole analogues as potential anti-inflammatory agents targeting 5-lipoxygenase.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1704051Inhibition of ovine COX-1 assessed as reduction in PGE2 level using 10 uM arachidonic acid as substrate preincubated with enzyme for 5 mins followed by substrate addition and measured after 20 mins by ELISA2020European journal of medicinal chemistry, Oct-15, Volume: 204Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core.
AID372035Reversible inhibition of human recombinant 5-lipoxygenase expressed in Escherichia coli assessed as 5LO product formation at 1 uM measured after 10-fold compound dilution by wash-out experiment in presence of exogenous arachidonic acid2009Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11
Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase.
AID1065367Inhibition of 5-LO (unknown origin) by cell based assay2013European journal of medicinal chemistry, Sep, Volume: 67Discovery and biological evaluation of novel 1,4-benzoquinone and related resorcinol derivatives that inhibit 5-lipoxygenase.
AID1424048Inhibition of human recombinant 5-LOX assessed as reduction in leukotriene B4 production pre-incubated for 10 mins before arachidonic acid addition and measured after 10 mins by ELISA2017Journal of natural products, 04-28, Volume: 80, Issue:4
Anti-inflammatory Activity of Natural Geranylated Flavonoids: Cyclooxygenase and Lipoxygenase Inhibitory Properties and Proteomic Analysis.
AID661903Inhibition of 5-lipoxygenase in cell free S100 freshly isolated human PMNL cells assessed as inhibition of A23187-stimulated 5-LO product formation preincubated for 15 mins measured after 10 mins by HPLC analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and biological evaluation of a class of 5-benzylidene-2-phenyl-thiazolinones as potent 5-lipoxygenase inhibitors.
AID1304627Inhibition of recombinant human 5-LO expressed in Escherichia coli MV1190 cells assessed as residual activity at 1 uM preincubated for 10 mins followed by addition of arachidonic acid as substrate measured after 10 mins by RP-HPLC method relative to contr2016Journal of natural products, Mar-25, Volume: 79, Issue:3
Humudifucol and Bioactive Prenylated Polyphenols from Hops (Humulus lupulus cv. "Cascade").
AID180524In vivo rat anaphylaxis leukotriene formation on an oral dose of 200 micro mol/Kg1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.
AID6919Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
AID89232In vitro inhibition of LTB4 synthesis in human whole blood.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
(Methoxyalkyl)thiazoles: a new series of potent, selective, and orally active 5-lipoxygenase inhibitors displaying high enantioselectivity.
AID216286In vitro inhibition of LTB4 formation in human whole blood(HWB)1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids.
AID657245Inhibition of potato 5-LOX by EIA2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Synthesis and biological evaluation of isoxazolo[4,5-d]pyridazin-4-(5H)-one analogues as potent anti-inflammatory agents.
AID67725-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Synthesis and antiinflammatory activity of certain 5,6,7,8-tetrahydroquinolines and related compounds.
AID1484243Inhibition of human A549 cell microsomal membrane-derived mPGES-1 assessed as reduction in conversion of PGH2 to PGE2 preincubated for 15 mins followed by PGH2 addition measured after 1 min by RP-HPLC analysis2017Journal of natural products, 03-24, Volume: 80, Issue:3
Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones.
AID179052In vitro inhibition of PGE-2 synthesis against rat whole blood.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
(Methoxyalkyl)thiazoles: a new series of potent, selective, and orally active 5-lipoxygenase inhibitors displaying high enantioselectivity.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1461593Inhibition of ovine COX-1 preincubated for 5 mins followed by arachidonic acid substrate addition by colorimetric enzyme immunoassay2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity.
AID1139557Binding affinity to human recombinant 5-LO ATP-bindng site using ATP-agaarose column in S40 fraction of Escherichia coli2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID625294Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID733347Inhibition of 5-LOX-mediated LTB4 formation in human whole blood at 10 uM incubated for 20 mins prior to substrate addition measured after 0.5 hrs by EIA in presence of calcium ionophore A231872013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Discovery of highly potent microsomal prostaglandin e2 synthase 1 inhibitors using the active conformation structural model and virtual screen.
AID6861Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors.
AID1579860Inhibition of LTC4S in asthmatic human whole blood assessed as inhibition of calcium ionophore A23187 stimulated cysteinyl leukotrienes production preincuabted for 30 mins followed by calcium ionophore stimulation and measured after 10 mins by LC-MS analy2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1
AID1653809Substrate activity at human mARC2 expressed in Escherichia coli assessed as turnover rates at 1 mM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by LC-MS analysis based assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID3629In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Synthesis and 5-lipoxygenase inhibitory activities of some novel 2-substituted 5-benzofuran hydroxamic acids.
AID404481Inhibition of PGF2apha production in arachidonic acid-stimulated mouse MC9 cells2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib.
AID1657000Plasma clearance in iv dosed cynomolgus monkey2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Acetylene Group, Friend or Foe in Medicinal Chemistry.
AID1615193Inhibition of human 5-LO transfected in HEK293 cells coexpressing FLAP assessed as reduction in leukotriene formation at 1 uM using arachidonic acid as substrate preincubated for 5 mins followed by calcium ionophore A23187/arachidonic acid addition and me2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery of a novel 2,5-dihydroxycinnamic acid-based 5-lipoxygenase inhibitor that induces apoptosis and may impair autophagic flux in RCC4 renal cancer cells.
AID1854722Inhibition of COX-1 (unknown origin) using arachidonic acid as substrate and measured by fluorometric assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
AID92869Inhibitory activity of the compound against Thromboxane TXB2 production in human whole blood1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase.
AID6903Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
AID1333392Inhibition of human recombinant 5-LOX expressed in Escherichia coli BL21 assessed as decrease in 5-HPETE production preincubated with enzyme followed by arachidonic acid substrate addition by UV-vis spectrophotometry2016European journal of medicinal chemistry, Nov-29, Volume: 124Inhibition of the enzymes in the leukotriene and prostaglandin pathways in inflammation by 3-aryl isocoumarins.
AID290449Inhibition of 5-LOX in rat peritoneal leukocytes at 5 uM2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Indole derivatives as potent inhibitors of 5-lipoxygenase: design, synthesis, biological evaluation, and molecular modeling.
AID102653In vitro activities of Leukotriene B4 receptor (LTB4) in human neutrophils1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase.
AID412945Inhibition of human recombinant 5-LO expressed in Escherichia coli by cell-free assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
AID223081Inhibitory activity was determined for LTB4 production in human whole blood.2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Structure-activity relationship studies on 1-[2-(4-Phenylphenoxy)ethyl]pyrrolidine (SC-22716), a potent inhibitor of leukotriene A(4) (LTA(4)) hydrolase.
AID1676599Binding affinity to cupric ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1484241Inhibition of human recombinant 5-LO expressed in Escherichia coli MV1190 using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by RP-HPLC analysis2017Journal of natural products, 03-24, Volume: 80, Issue:3
Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones.
AID775827Binding affinity to human holo-transferrin assessed as pseudo-first-order rate constant measured as removal of ferric ion at 1 mM measured for 1 hr by UV-vis spectrophotometric analysis2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Investigating the selectivity of metalloenzyme inhibitors.
AID160401Inhibition activity against recombinant human Prostaglandin G/H synthase 21997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors.
AID6897Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
AID6709In vitro potency against human 5-Lipoxygenase1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids.
AID1676595Binding affinity to Ferric ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1657001Half life in cynomolgus monkey2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Acetylene Group, Friend or Foe in Medicinal Chemistry.
AID1461765Inhibition of 5-LO in fMLP-stimulated human neutrophils by HPLC analysis2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
Recent synthetic and medicinal perspectives of tryptanthrin.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1676594Binding affinity to gallium ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID101303Ex vivo inhibition of LTB-4 determined by measurement of A-23187-stimulated LTB-4 production in dog blood at 1 mg/kg iv1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1676597Binding affinity to cupric ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1143901Inhibition of 5-LO-mediated LTB4 production in human polymorphonuclear leukocytes assessed as assessed as remaining activity preincubated at 10 uM for 15 mins by HPLC analysis2014European journal of medicinal chemistry, Jun-23, Volume: 81Further studies on ethyl 5-hydroxy-indole-3-carboxylate scaffold: design, synthesis and evaluation of 2-phenylthiomethyl-indole derivatives as efficient inhibitors of human 5-lipoxygenase.
AID488197Inhibition of 5-lipoxygenase in human whole blood assessed as inhibition of LTB4 production by HPLC method2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Synthesis and biological activity of N-aroyl-tetrahydro-gamma-carbolines.
AID6821In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Synthesis and 5-lipoxygenase inhibitory activities of some novel 2-substituted 5-benzofuran hydroxamic acids.
AID1184089Cytotoxicity against human U937 cells at 100 uM after 48 hrs by LDH assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Multi-dimensional target profiling of N,4-diaryl-1,3-thiazole-2-amines as potent inhibitors of eicosanoid metabolism.
AID1704052Inhibition of human recombinant COX-2 assessed as reduction in PGE2 level using 10 uM arachidonic acid as substrate preincubated with enzyme for 5 mins followed by substrate addition and measured after 20 mins by ELISA2020European journal of medicinal chemistry, Oct-15, Volume: 204Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core.
AID1704054Inhibition of human recombinant 5-LOX assessed as reduction in LTB4 level using 800 uM arachidonic acid as substrate preincubated with enzyme for 10 mins followed by substrate addition and measured after 10 mins by ELISA2020European journal of medicinal chemistry, Oct-15, Volume: 204Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core.
AID488198Inhibition of 5-lipoxygenase in human whole blood assessed as inhibition of 5-hydroxyeicosatetraenoic acid production by HPLC method2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Synthesis and biological activity of N-aroyl-tetrahydro-gamma-carbolines.
AID6921Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
AID6955Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application i
AID89233In vitro inhibition of TXB2 synthesis in human whole blood.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
(Methoxyalkyl)thiazoles: a new series of potent, selective, and orally active 5-lipoxygenase inhibitors displaying high enantioselectivity.
AID669533Inhibition of 5-lipoxygenase/FLAP in calcium Ionophore-stimulated human whole blood assessed as residual 12(s)HETE level at 5 uM preincubated for 15 mins prior to calcium ionophore-stimulation measured after 15 mins by LC-MS/MS analysis2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
Structure-activity relationship of nonacidic quinazolinone inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1).
AID1858313Anti-inflammatory activity against OVA-sensitized asthmatic BALB/c mouse model assessed as effect on OVA-sensitization by measuring IL-13 levels in lungs at 35 mg/kg, ip administered 30 mins prior to OVA challenge on days 0 and 7 and measured on day 21 by
AID160515Test inhibition of LTB4 production in human peripheral blood polymorphonuclear leukocytes (HPMN)1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.
AID1569917Inhibition of ovine COX-1 using arachidonic acid as substrate incubated for 5 mins by fluorescence-based assay
AID1057867Inhibition of calcium ionophore (A23187)-stimulated human 5-LO assessed as reduction of 15(S)-HETE production by measuring remaining activity at 5 uM preincubated for 15 mins followed by calcium ionophore (A23187) addition measured after 15 mins by LC-MS/2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Synthesis and pharmacological characterization of benzenesulfonamides as dual species inhibitors of human and murine mPGES-1.
AID248953Inhibitory concentration against 5-lipoxygenase in human whole blood2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds.
AID1139552Inhibition of 5-LO in human neutrophils assessed as product formation at 3 uM by cell-intact assay relative to control in presence of 2.5 uM A23187 ionophore2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase.
AID488193Inhibition of 5-lipoxygenase in human whole blood2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Synthesis and biological activity of N-aroyl-tetrahydro-gamma-carbolines.
AID363323Inhibition of 5LOX in human whole blood assessed as inhibition of calcium ionophore A-stimulated 5-HETE production at 0.7 uM2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Synthesis and biological activities of a series of 4,5-diaryl-3-hydroxy-2(5H)-furanones.
AID6948In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
AID1057873Inhibition of calcium ionophore (A23187)-stimulated human 5-LO assessed as reduction of LTB4 production by measuring remaining activity at 5 uM preincubated for 15 mins followed by calcium ionophore (A23187) addition measured after 15 mins by LC-MS/MS ana2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Synthesis and pharmacological characterization of benzenesulfonamides as dual species inhibitors of human and murine mPGES-1.
AID99747Inhibitory activity was determined against Leukotriene A4 hydrolase2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Structure-activity relationship studies on 1-[2-(4-Phenylphenoxy)ethyl]pyrrolidine (SC-22716), a potent inhibitor of leukotriene A(4) (LTA(4)) hydrolase.
AID1420843Inhibition of recombinant human 5-LOX pseudoperoxidase activity expressed in Escherichia coli BL21 assessed as compound redox activity by measuring decrease in 13(S)-HpODE product formation at 10 uM by UV-vis spectrophotometric method2018European journal of medicinal chemistry, Oct-05, Volume: 158Design, synthesis and identification of novel substituted 2-amino thiazole analogues as potential anti-inflammatory agents targeting 5-lipoxygenase.
AID101302Duration of action where maximum inhibition of LTB4 formation is achieved at 1 mg/kg po1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors.
AID1676590Binding affinity to Nickel cation assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1406147Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using p-tyramine as substrate pretreated for 15 mins followed by substrate addition by horse-radish peroxidase/amplex red-based fluorescence method2018European journal of medicinal chemistry, Aug-05, Volume: 156Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID493017Wombat Data for BeliefDocking1992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Development of 2,3-dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1799727In Vitro 5-LOX Assay from Article 10.1111/j.1747-0285.2012.01371.x: \\Synthesis and Biological Evaluation of N-aryl-4-aryl-1,3-Thiazole-2-Amine Derivatives as Direct 5-Lipoxygenase Inhibitors.\\2012Chemical biology & drug design, Jul, Volume: 80, Issue:1
Synthesis and biological evaluation of N-aryl-4-aryl-1,3-thiazole-2-amine derivatives as direct 5-lipoxygenase inhibitors.
AID1801112COX1 and COX2 Inhibition Assay from Article 10.1111/cbdd.12469: \\Enzymatic Studies of Isoflavonoids as Selective and Potent Inhibitors of Human Leukocyte 5-Lipo-Oxygenase.\\2015Chemical biology & drug design, Jul, Volume: 86, Issue:1
Enzymatic Studies of Isoflavonoids as Selective and Potent Inhibitors of Human Leukocyte 5-Lipo-Oxygenase.
AID1801075Cell-Free Assay from Article 10.1111/cbdd.12356: \\Identification of 1, 4-Dihydrothieno [3', 2':5, 6]thiopyrano[4, 3-c] pyrazole derivatives as human 5-Lipo-oxygenase inhibitors.\\2014Chemical biology & drug design, Dec, Volume: 84, Issue:6
Identification of 1, 4-Dihydrothieno [3', 2':5, 6]thiopyrano[4, 3-c] pyrazole derivatives as human 5-Lipo-oxygenase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (527)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's184 (34.91)18.2507
2000's127 (24.10)29.6817
2010's171 (32.45)24.3611
2020's45 (8.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.67 (24.57)
Research Supply Index6.42 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index107.53 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (62.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials64 (11.62%)5.53%
Reviews56 (10.16%)6.00%
Case Studies7 (1.27%)4.05%
Observational0 (0.00%)0.25%
Other424 (76.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (19)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase I Study to Evaluate the Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in Patients With Chronic Myelogenous Leukemia [NCT01130688]Phase 12 participants (Actual)Interventional2010-01-31Terminated(stopped due to Lack of enrollment)
Noninvasive Quantification of the Pulmonary Anti-inflammatory Effect of Rosiglitazone [NCT01174056]Early Phase 139 participants (Actual)Interventional2011-07-31Completed
Evaluation of Additive Effects of Zileuton to Advair on Total Exhaled, Bronchial, and Alveolar Nitric Oxide in Asthmatics [NCT00575861]Phase 419 participants (Actual)Interventional2005-09-30Completed
Phase I Trial of Zileuton CR in Children and Adults With Sickle Cell Disease [NCT01136941]Phase 19 participants (Actual)Interventional2010-09-30Completed
Clinical Study of the Effect of Combined Treatment of Aspirin and Zileuton on Biomarkers of Tobacco-Related Carcinogenesis in Current Smokers [NCT02348203]Phase 263 participants (Actual)Interventional2016-01-13Completed
Phase 2 Study of the Assessment of Pulmonary Function, Safety, Tolerability, and PK of Zileuton Injection in Patients With Chronic Stable Asthma [NCT00534625]Phase 236 participants (Actual)Interventional2007-09-30Completed
Antileukotriene Therapy for COPD Exacerbations [NCT00493974]Phase 3119 participants (Actual)Interventional2007-03-31Terminated(stopped due to Lack of feasibility due to low recruitment)
A Phase 2a, Randomised, Double-Blind (3rd Party Open), Double-Dummy, Placebo And Active Controlled 5-Way Crossover Study To Assess The Bronchodilatory Action, Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04191834 In Asthmatic Patient [NCT00723021]Phase 215 participants (Actual)Interventional2008-07-31Completed
Modulation of Arachidonic Acid Metabolism by Chemopreventive Agents in Smokers [NCT01021215]Phase 1/Phase 284 participants (Actual)Interventional2010-05-31Completed
Phase I Study to Evaluate the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Patients With Chronic Myelogenous Leukemia [NCT02047149]Phase 12 participants (Actual)Interventional2014-01-31Terminated(stopped due to Low accrual)
Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome [NCT00467831]Phase 1/Phase 23 participants (Actual)Interventional2007-04-30Terminated(stopped due to insufficient enrollment)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Proof of Concept Study of Zileuton IR in Patients With Moderate to Severe Facial Acne Vulgaris [NCT00098358]Phase 290 participants Interventional2004-11-30Active, not recruiting
Phase II Trial of Zileuton Compared to Azathioprine/Prednisone for the Treatment of Idiopathic Pulmonary Fibrosis [NCT00262405]Phase 244 participants (Actual)Interventional2001-01-31Completed
Assessment of Safety, Tolerability, and Pharmacokinetics of Zileuton Injection in Patients With Asthma [NCT00299065]Phase 1/Phase 260 participants Interventional2006-01-31Completed
A Randomized, Double-Blind, Placebo Controlled Study of Zileuton CR Tablets Versus Placebo in Adult Patients With Poorly Controlled Asthma Patients on Moderate Dose Inhaled Corticosteroids (ICS) [NCT00486343]Phase 4400 participants (Anticipated)Interventional2007-07-31Terminated(stopped due to Slower than anticipated enrollment)
Randomized Phase II Study of Eicosanoid Pathway Modulators and Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer [NCT00070486]Phase 2140 participants (Actual)Interventional2003-12-31Completed
A Single-Center, Open-Label, Single-Dose Evaluation of the Duration and Extent of Bronchodilation Following Administration of Zileuton CR 1200 mg in Subjects With Stable, Chronic Asthma [NCT01805687]Phase 425 participants (Actual)Interventional2013-03-31Completed
Phase II Trial Of Zileuton In Persons With Bronchial Dysplasia [NCT00056004]Phase 238 participants (Actual)Interventional2003-06-30Completed
Comparative Efficacy of Carbamazepine Versus Oxcarbazepine in Treatment of Trigeminal Neuralgia- a Randomized Controlled Clinical Study [NCT04996199]Phase 4132 participants (Anticipated)Interventional2021-09-18Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00467831 (1) [back to overview]Survival at 2 Years
NCT00493974 (7) [back to overview]Change in FEV1/FEV6 Levels
NCT00493974 (7) [back to overview]Change in FEV1% Predicted
NCT00493974 (7) [back to overview]Change in Urinary Leukotriene (LTE4) Levels
NCT00493974 (7) [back to overview]Change in Urinary Leukotriene (LTE4) Levels
NCT00493974 (7) [back to overview]Health-related Quality of Life
NCT00493974 (7) [back to overview]Length of Hospital Stay
NCT00493974 (7) [back to overview]Treatment Failure
NCT00723021 (9) [back to overview]Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
NCT00723021 (9) [back to overview]Maximum Observed Plasma Concentration (Cmax)
NCT00723021 (9) [back to overview]Time to Reach Maximum Observed Plasma Concentration (Tmax)
NCT00723021 (9) [back to overview]Change From Baseline in Forced Expiratory Flow Between 25 and 75% of Vital Capacity (FEF25-75)
NCT00723021 (9) [back to overview]Change From Baseline in Forced Expiratory Flow Between 25 and 75% of Vital Capacity (FEF25-75)
NCT00723021 (9) [back to overview]Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
NCT00723021 (9) [back to overview]Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
NCT00723021 (9) [back to overview]Change From Baseline in Forced Vital Capacity (FVC)
NCT00723021 (9) [back to overview]Change From Baseline in Forced Vital Capacity (FVC)
NCT01021215 (3) [back to overview]Proportion of Cases With a Post-treatment Increase in Urinary PGE-M Levels
NCT01021215 (3) [back to overview]Median Urinary LTE4 Levels (Pre and Post Treatment)
NCT01021215 (3) [back to overview]Median Urinary PGE-M Levels (Pre and Post Treatment)
NCT01805687 (1) [back to overview]Change From Baseline in FEV1
NCT02348203 (9) [back to overview]Change in Urinary LTE (4) Levels
NCT02348203 (9) [back to overview]Change in Urinary PGE-M Levels
NCT02348203 (9) [back to overview]Changes in a Smoking-related Gene Expression Signature Score in the Nasal Epithelium of Current Smokers
NCT02348203 (9) [back to overview]Changes in a Smoking-related Gene Expression Signature Score in the Nasal Epithelium of Current Smokers 10-14 Days Post Intervention
NCT02348203 (9) [back to overview]Number of Genes Differentially Expressed After Aspirin and Zileuton Intervention Compared to Placebo
NCT02348203 (9) [back to overview]Number of Participants Experiencing Possibly/Probably/Definitely-related Adverse Events
NCT02348203 (9) [back to overview]Changes in Three Lung Cancer Gene Signatures (an 80-gene Bronchial Signature, a PI3K Pathway Gene Signature and a Nasal Diagnostic Gene Signature) in the Nasal Epithelium of Current Smokers
NCT02348203 (9) [back to overview]Changes in Three Lung Cancer Gene Signatures (an 80-gene Bronchial Signature, a PI3K Pathway Gene Signature and a Nasal Diagnostic Gene Signature) in the Nasal Epithelium of Current Smokers 10-14 Days Post Intervention
NCT02348203 (9) [back to overview]Gender Effect on Smoking-related Gene Expression Signature

Survival at 2 Years

The number of subjects surviving after 24 months on study. (NCT00467831)
Timeframe: 24 months

Interventionparticipants (Number)
Multi-Drug Regimen0

[back to top]

Change in FEV1/FEV6 Levels

Change in Post-bronchodilator FEV1/FEV6 ratio comparing data at discharge visit with baseline. (NCT00493974)
Timeframe: from baseline to day of discharge

Interventionratio (Mean)
Zileuton0.02
Placebo0.03

[back to top]

Change in FEV1% Predicted

Change in Post-bronchodilator FEV1% predicted comparing data at 30 day visit with baseline. (NCT00493974)
Timeframe: Measured at Baseline and Day 30

Interventionpercent predicted (Mean)
Zileuton6.8
Placebo8.0

[back to top]

Change in Urinary Leukotriene (LTE4) Levels

Change in natural log-transformed LTE4 (ng/mg Cr.) from Baseline to 24 Hours (NCT00493974)
Timeframe: Baseline and 24 hours

Intervention(ng/mg Cr.) (Log Mean)
Zileuton-1.38
Placebo0.14

[back to top]

Change in Urinary Leukotriene (LTE4) Levels

Change in natural log-transformed LTE4 (ng/mg Cr.) from Baseline to 72 Hours (NCT00493974)
Timeframe: Baseline and 72 hours later

Intervention(ng/mg Cr.) (Log Mean)
Zileuton-1.32
Placebo0.26

[back to top] [back to top]

Length of Hospital Stay

Admission will begin at the time the subject has been admitted to an inpatient service. Length of Stay (LOS) will be recorded in days. The LOS will be based on the number of days spent in an acute medical ward or in the ICU. Subjects that are admitted and discharged in the same 24 hour period will be recorded as a LOS of 1 day, as will subjects discharged in the ensuing 24 hour period. LOS's greater than 10 days will be truncated to 10 days. (NCT00493974)
Timeframe: Measured at Day 30

InterventionDays (Median)
Zileuton3
Placebo3

[back to top]

Treatment Failure

Treatment failure is defined as death, intubation, readmission to a hospital for COPD, urgent visit to an outpatient or ED provider for symptoms of COPD or intensification of therapy [including second course of antibiotics for COPD, and second course of systemic steroids for COPD]) in the first 30 days after randomization. (NCT00493974)
Timeframe: Baseline to day 30 visit

,
InterventionParticipants (Number)
DeathIntubationHospital ReadmissionUrgent VisitIntensification of therapyAny Treatment Failure
Placebo21761116
Zileuton11771114

[back to top]

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) (NCT00723021)
Timeframe: Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period.

Interventionng*h/mL (Mean)
PF-04191834 30 mg1979
PF-04191834 100 mg5547
PF-04191834 2000 mg29990

[back to top]

Maximum Observed Plasma Concentration (Cmax)

(NCT00723021)
Timeframe: Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period.

Interventionng/mL (Mean)
PF-04191834 30 mg154
PF-04191834 100 mg426
PF-04191834 2000 mg2146

[back to top]

Time to Reach Maximum Observed Plasma Concentration (Tmax)

(NCT00723021)
Timeframe: Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period.

Interventionhrs (Median)
PF-04191834 30 mg6
PF-04191834 100 mg6
PF-04191834 2000 mg10

[back to top]

Change From Baseline in Forced Expiratory Flow Between 25 and 75% of Vital Capacity (FEF25-75)

The FEF25-75 is the forced expiratory flow between 25 and 75% of vital capacity (NCT00723021)
Timeframe: Baseline, 12 hours (hrs) post-dose

,,,,
InterventionL/Sec (Mean)
BaselineChange at 12 Hours Postdose
PF-04191834 100 mg1.8070.269
PF-04191834 2000 mg1.9150.297
PF-04191834 30 mg1.9010.340
Placebo1.9510.091
Zileuton CR 1200 mg1.9590.187

[back to top]

Change From Baseline in Forced Expiratory Flow Between 25 and 75% of Vital Capacity (FEF25-75)

The FEF25-75 is the forced expiratory flow between 25 and 75% of vital capacity (NCT00723021)
Timeframe: Baseline, 24 hours (hrs) post-dose

,,,,
InterventionL (Mean)
BaselineChange at 24 Hours Postdose
PF-04191834 100 mg1.8070.196
PF-04191834 2000 mg1.9150.151
PF-04191834 30 mg1.9010.038
Placebo1.9510.146
Zileuton CR 1200 mg1.9590.208

[back to top]

Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)

The FEV1 is the maximal volume of air that can be forcefully exhaled in one second (NCT00723021)
Timeframe: Baseline, 12 hours (hrs) post-dose

,,,,
InterventionL (Mean)
BaselineChange at 12 Hours Postdose
PF-04191834 100 mg2.5850.152
PF-04191834 2000 mg2.5790.265
PF-04191834 30 mg2.6260.164
Placebo2.6240.064
Zileuton CR 1200 mg2.6090.131

[back to top]

Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)

The FEV1 is the maximal volume of air that can be forcefully exhaled in one second (NCT00723021)
Timeframe: Baseline, 24 hours (hrs) post-dose

,,,,
InterventionL (Mean)
BaselineChange at 24 Hours Postdose
PF-04191834 100 mg2.5850.103
PF-04191834 2000 mg2.5790.162
PF-04191834 30 mg2.6260.014
Placebo2.6240.122
Zileuton CR 1200 mg2.6090.151

[back to top]

Change From Baseline in Forced Vital Capacity (FVC)

The FVC is the maximal volume of air that can be exhaled from full inhalation by exhaling as forcefully and rapidly as possible (NCT00723021)
Timeframe: Baseline, 12 hours (hrs) post-dose

,,,,
InterventionL (Mean)
BaselineChange at 12 Hours Postdose
PF-04191834 100 mg3.7200.210
PF-04191834 2000 mg3.7920.266
PF-04191834 30 mg3.8910.284
Placebo3.8520.025
Zileuton CR 1200 mg3.8210.140

[back to top]

Change From Baseline in Forced Vital Capacity (FVC)

The FVC is the maximal volume of air that can be exhaled from full inhalation by exhaling as forcefully and rapidly as possible (NCT00723021)
Timeframe: Baseline,24 hours (hrs) post-dose

,,,,
InterventionL (Mean)
BaselineChange at 24 Hours Postdose
PF-04191834 100 mg3.7200.229
PF-04191834 2000 mg3.7920.171
PF-04191834 30 mg3.8910.051
Placebo3.8520.162
Zileuton CR 1200 mg3.8210.219

[back to top]

Proportion of Cases With a Post-treatment Increase in Urinary PGE-M Levels

Proportion of cases with a post-treatment increase in urinary PGE-M levels by comparing those treated with Zileuton and Celecoxib combined therapy compared to those treated with Zileuton alone. Pre/postchange in levels (Increase) derived from baseline level to Day 6 +/- 1 day. Differences in baseline levels between 2 treatment arms were examined using the Wilcoxon rank-sum test. (NCT01021215)
Timeframe: Baseline to Day 6

Interventionproportion of participants (Number)
Arm I: Zileuton.37
Arm II: Zileuton and Celecoxib.06

[back to top]

Median Urinary LTE4 Levels (Pre and Post Treatment)

Pre and Post treatment differences in urinary LTE4 levels measured in each treatment arm compared using paired t-test should the data conform to the normality assumption or one-sample Wilcoxon rank-sum test. LTE4 levels reported as median with full range (pg/mg creatinine) for Pre treatment versus Post treatment LTE4 levels among study participants compliant to treatment with evaluable urine samples at both time points (baseline and Day 6 +/- 1 day). (NCT01021215)
Timeframe: Baseline and day 6

,
Interventionpg/mg creatinine (Median)
Pre LTE4 levelsPost LTE4 levels
Arm I: Zileuton10742
Arm II: Zileuton and Celecoxib8630

[back to top]

Median Urinary PGE-M Levels (Pre and Post Treatment)

Pre and Post treatment differences in urinary PGE-M levels measured in each treatment arm. PGE-M levels reported as median with full range (ng/mg creatinine) for Pre treatment versus Post treatment PGE-M levels among study participants compliant to treatment with evaluable urine samples at both time points (baseline and Day 6 +/- 1 day). (NCT01021215)
Timeframe: Baseline and Day 6

,
Interventionng/mg creatinine (Median)
Pre PGE-M LevelsPost PGE-M Levels
Arm I: Zileuton12.810.5
Arm II: Zileuton and Celecoxib13.43.9

[back to top]

Change From Baseline in FEV1

(NCT01805687)
Timeframe: 12 Hours

InterventionLiter (Mean)
Zileuton Extended Release2.84

[back to top]

Change in Urinary LTE (4) Levels

(NCT02348203)
Timeframe: Baseline to 12 weeks (End-of-intervention)

Interventionpg/mg creatinine (Mean)
Arm I (Aspirin, Zileuton)-57.6
Arm II (Double Placebo)35.2

[back to top]

Change in Urinary PGE-M Levels

(NCT02348203)
Timeframe: Baseline to 12 weeks (End-of-intervention)

Interventionng/mg creatinine (Mean)
Arm I (Aspirin, Zileuton)-5.9
Arm II (Double Placebo)0.71

[back to top] [back to top]

Changes in a Smoking-related Gene Expression Signature Score in the Nasal Epithelium of Current Smokers 10-14 Days Post Intervention

Change (from baseline to 10-14 days off intervention) in a nasal smoking-related gene expression signature score derived from prior research was compared between the two study arms. Prior research showed that a higher score was observed in never smokers compared to current smokers. An increased score implicated a more favorable intervention effect. There is no minimum or maximum score. (NCT02348203)
Timeframe: Baseline to 14 days post intervention

Interventionscore on a scale (Mean)
Arm I (Aspirin, Zileuton)-0.24
Arm II (Double Placebo)-1.16

[back to top]

Number of Genes Differentially Expressed After Aspirin and Zileuton Intervention Compared to Placebo

Number of genes differentially expressed after aspirin and zileuton intervention compared to placebo using whole-genome gene expression data (NCT02348203)
Timeframe: Baseline to 12 weeks (End-of-intervention)

Interventiongene (Number)
Arm I (Aspirin, Zileuton)83
Arm II (Double Placebo)0

[back to top] [back to top]

Changes in Three Lung Cancer Gene Signatures (an 80-gene Bronchial Signature, a PI3K Pathway Gene Signature and a Nasal Diagnostic Gene Signature) in the Nasal Epithelium of Current Smokers

Change in three lung cancer gene signatures (an 80-gene bronchial signature, a PI3K pathway gene signature and a nasal diagnostic gene signature) derived from prior research was compared between the two study arms. A decreased signature score implicated a more favorable intervention effect. There is no minimum or maximum score. (NCT02348203)
Timeframe: Baseline to 12 weeks (End of Intervention)

,
Interventionscore on a scale (Mean)
bronchial smoking signaturePI3 pathway gene signaturenasal diagnostic gene signature
Arm I (Aspirin, Zileuton)-1.0-0.321.82
Arm II (Double Placebo)-0.430.422.17

[back to top]

Changes in Three Lung Cancer Gene Signatures (an 80-gene Bronchial Signature, a PI3K Pathway Gene Signature and a Nasal Diagnostic Gene Signature) in the Nasal Epithelium of Current Smokers 10-14 Days Post Intervention

Change (from baseline to 10-14 days off intervention) in three lung cancer gene signatures (an 80-gene bronchial signature, a PI3K pathway gene signature and a nasal diagnostic gene signature) derived from prior research was compared between the two study arms. A decreased signature score implicated a more favorable intervention effect. There is no minimum or maximum score. (NCT02348203)
Timeframe: Baseline to 14 days post intervention

,
Interventionscore on a scale (Mean)
bronchial signaturePI3K pathway gene signaturenasal diagnostic gene signature
Arm I (Aspirin, Zileuton)-1.37-0.162.78
Arm II (Double Placebo)0.880.71-1.98

[back to top] [back to top]